<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>   <meta charset="utf-8" />
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<link rel=File-List href="onkoloji_dosyalar/filelist.xml">
<link rel=Edit-Time-Data href="onkoloji_dosyalar/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>N�RO-ONKOLOJ&#304;</title>
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421319 -2147483648 8 0 66047 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h2
	{mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	mso-outline-level:2;
	font-size:18.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
p
	{mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.dzeltme, li.dzeltme, div.dzeltme
	{mso-style-name:dzeltme;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
span.msons
	{mso-style-name:mso\0131ns;
	text-decoration:underline;
	text-underline:single;}
span.msodel0
	{mso-style-name:msodel;
	color:red;
	text-decoration:line-through;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:70.85pt 70.85pt 70.85pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 @list l0
	{mso-list-id:52310603;
	mso-list-type:hybrid;
	mso-list-template-ids:1844508232 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1
	{mso-list-id:64183340;
	mso-list-template-ids:-2017965868;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l2
	{mso-list-id:64960796;
	mso-list-template-ids:1387163614;}
@list l2:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l3
	{mso-list-id:259025450;
	mso-list-template-ids:1438812400;}
@list l3:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l4
	{mso-list-id:626276504;
	mso-list-template-ids:-1137162906;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l5
	{mso-list-id:704603199;
	mso-list-type:hybrid;
	mso-list-template-ids:139478852 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l5:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l5:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6
	{mso-list-id:821579602;
	mso-list-template-ids:2014490080;}
@list l6:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l7
	{mso-list-id:884174953;
	mso-list-template-ids:-1872969842;}
@list l7:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l8
	{mso-list-id:960187075;
	mso-list-template-ids:-1054825630;}
@list l8:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l9
	{mso-list-id:1184976250;
	mso-list-type:hybrid;
	mso-list-template-ids:406593606 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l9:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l9:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l10
	{mso-list-id:1219434258;
	mso-list-template-ids:1782080580;}
@list l10:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l11
	{mso-list-id:1404639509;
	mso-list-type:hybrid;
	mso-list-template-ids:-641023698 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l11:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l11:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12
	{mso-list-id:1425418758;
	mso-list-type:hybrid;
	mso-list-template-ids:-529001096 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l12:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l12:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l13
	{mso-list-id:1529374179;
	mso-list-template-ids:-242698810;}
@list l13:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l14
	{mso-list-id:1690183908;
	mso-list-template-ids:-784795596;}
@list l14:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l15
	{mso-list-id:1789540707;
	mso-list-template-ids:-1674248846;}
@list l15:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l16
	{mso-list-id:1789548008;
	mso-list-type:hybrid;
	mso-list-template-ids:1787471864 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l16:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l16:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17
	{mso-list-id:2051222365;
	mso-list-type:hybrid;
	mso-list-template-ids:-1433254462 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l17:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l17:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Normal Tablo";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
table.MsoTableGrid
	{mso-style-name:"Tablo K\0131lavuzu";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	border:solid windowtext 1.0pt;
	mso-border-alt:solid windowtext .5pt;
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-border-insideh:.5pt solid windowtext;
	mso-border-insidev:.5pt solid windowtext;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
</style>
<![endif]-->
</head>

<body lang=EN-US link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�RO-ONKOLOJ&#304;</span></h2>

<h2><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Erdem T�z�n, G�l&#351;en Akman Demir, Jale Yaz&#305;c&#305;</span></h2>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Son
g�ncelle&#351;tirme tarihi: 1. 7. 2009</span></b><a name=G&#304;R&#304;&#350;></a></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Resim i�ermeyen bu b�l�mde yer alan t�m�ral olu&#351;umlar&#305;n
bir�o&#287;una ait makroskopik ve histopatolojik &#351;ekiller <span
style='color:#0070C0'><a href="../noropatoloji/noropatoloji.htm">Sinir Sistemi
Semiyolojisi/N�rolojide Laboratuvar &#304;ncelemeleri/<b>N�ropatoloji</b></a></span>
b�l�m�nde bulunabilir. </span></p>

</div>

<p><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>G&#304;R&#304;&#350;</span></b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma;mso-ansi-language:TR'> </span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Sinir
sisteminin t�m�rlerle �e&#351;itli ili&#351;kilerini inceleyen bir bilim
dal&#305; olan n�ro-onkolojinin kapsam&#305; i�inde primer sinir sistemi
t�m�rlerinin yan&#305; s&#305;ra sistemik kanserlerin n�rolojik etkileri
(metastaz, lokal yay&#305;l&#305;m, radyoterapi veya kemoterapi yan etkileri,
t�m�r�n hematolojik-metabolik uzak etkileri ve paraneoplastik sendromlar) yer
al&#305;r. </span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p><a name="PR&#304;MER_BEY&#304;N"></a><b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma;mso-ansi-language:TR'>PR&#304;MER BEY&#304;N T�M�RLER&#304;</span></b><span
lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Primer veya
sekonder beyin t�m�rlerinde t�m�r�n davran&#305;&#351; �zellikleri birbirinden
farkl&#305;l&#305;k g�sterse de genelde kar&#351;&#305;la&#351;&#305;lan klinik
tablo kafa i�i bas&#305;n� art&#305;&#351;&#305; sendromudur. Ayr&#305;ca
t�m�r�n lokalizasyonuna g�re de&#287;i&#351;en �e&#351;itli n�rolojik belirti
ve bulgular ve/veya epileptik n�betler g�r�lebilir. Bu b�l�mde t�m�rlerin
yaratt&#305;&#287;&#305; klinik tablolar&#305;n �zerinde durulmayacakt&#305;r;
t�m�re ba&#287;l&#305; ortaya �&#305;kan metabolik sorunlar&#305;n sinir
sistemi �zerindeki etkileri de k&#305;saca s&#305;ralanacakt&#305;r; dileyen
okur bu kitapta yer alan ve bu konular&#305;n anlat&#305;ld&#305;&#287;&#305;
di&#287;er b�l�mlere ba&#351;vurabilir ( Bak&#305;n&#305;z: &nbsp;<span
style='color:#4F81BD'><a href="../kibas/kibas.htm">Kafa i�i bas&#305;nc&#305;
de&#287;i&#351;iklikleri</a></span>, <span style='color:#4F81BD'><a
href="../epilepsi/Epilepsi.htm">Epilepsi</a></span>, <span style='color:#4F81BD'><a
href="../beslenme/beslenme.htm">Sinir sisteminin nutrisyonel
hastal&#305;klar&#305;</a></span>). </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidemiyoloji</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kansere
ba&#287;l&#305; �l�mler aras&#305;nda primer beyin t�m�rleri g�rece k���k bir
b�l�m� olu&#351;turur (y&#305;lda yakla&#351;&#305;k 100 000�de 3000). Ancak bu
rakam&#305;n yakla&#351;&#305;k 10 kat&#305; kadar bir grupta da di&#287;er
kanserlerin komplikasyonlar&#305; sonucu MSS�nin tutulmas&#305; ile �l�m ortaya
�&#305;kar. Amerika Birle&#351;ik Devletleri�nde ortalama 300 milyonluk bir
n�fusta her y&#305;l yakla&#351;&#305;k 24 000 yeni primer beyin t�m�r�
tan&#305;s&#305; konmaktad&#305;r. T�rkiye�de ise kesin bir rakam verilememekle
birlikte oran&#305;n benzer oldu&#287;u san&#305;lmaktad&#305;r.
Eri&#351;kinlere k&#305;yasla �ocuklarda primer beyin t�m�rlerinin g�r�lme
s&#305;kl&#305;&#287;&#305; y�ksek olup, l�seminin ard&#305;ndan ikinci
s&#305;ray&#305; al&#305;r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Primer beyin
t�m�rleri i�inde en s&#305;k g�r�len gliomlard&#305;r (% 50), bunu meningiomlar
(% 15) izler (<b>Tablo 1</b>). �ocuklarda ise da&#287;&#305;l&#305;m daha
farkl&#305;d&#305;r (<b>Tablo 2</b>). Ayr&#305;ca eri&#351;kinlerde primer
beyin t�m�rleri s&#305;kl&#305;kla (% 70) supratentoriyal yerle&#351;im
g�sterirken, �ocuklarda infratentoriyal yerle&#351;im % 70
oran&#305;ndad&#305;r. &#350;iddetli ba&#351;a&#287;r&#305;s&#305; anamneziyle
getirilen bir �ocukta, tan&#305; olas&#305;l&#305;klar&#305; i�inde arka �ukur
t�m�r� ilk s&#305;rada olmal&#305;d&#305;r<i>.</i> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>S&#305;n&#305;flama</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Primer beyin
t�m�rleri ile ilgili D�nya Sa&#287;l&#305;k �rg�t�n�n (WHO) son
s&#305;n&#305;flamas&#305;nda, gliomlar&#305;n en s&#305;k tipi olan diff�z
astrositik t�m�rler 4 gruba ayr&#305;lm&#305;&#351;t&#305;r: <br>
&nbsp; </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='mso-list:l17 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>grad 1 astrositom
     (�ok nadirdir ve hamartomdan ay&#305;rdedilmesi g��t�r), </span><span
     lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></li>
 <li class=MsoNormal style='mso-list:l17 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>grad 2 astrositom,
     </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
 <li class=MsoNormal style='mso-list:l17 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>grad 3 anaplastik
     astrositom </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
 <li class=MsoNormal style='mso-list:l17 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>grad 4
     glioblastoma multiforme. <br>
     &nbsp; </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
</ul>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Burada gerek
atipi, damarlanma, mitoz �zellikleri ile karakterize b�y�me potansiyeli,
gerekse prognoz bak&#305;m&#305;ndan giderek k�t�le&#351;me s�z konusudur. Bu
s&#305;n&#305;flaman&#305;n d&#305;&#351;&#305;nda tutulan gliomlar da
vard&#305;r. �zellikle �ocuklarda ve gen�lerde g�r�len pilositik astrositom
(WHO grad 1�e denk gelir) ve ayr&#305;ca dev h�creli astrositom farkl&#305;
b�y�me ve s&#305;n&#305;rlanma �zellikleri ve farkl&#305; prognozlar&#305; nedeniyle
genellikle ayr&#305; ele al&#305;n&#305;r. Ependimomlar da h�cre tipine g�re 4
alt gruba ayr&#305;l&#305;r. Benzer &#351;ekilde oligodendroglial t�m�rler de
ayr&#305; bir kategoride ele al&#305;n&#305;r (WHO grad 2: oligodendrogliom,
WHO grad 3: anaplastik oligodendrogliom ve mikst gliomlar). Meningiomlar da
h�cre yap&#305;s&#305; a�&#305;s&#305;ndan alt gruplara ayr&#305;l&#305;r:
meningotelyal (sinsisyal) tip, anaplastik (habis) tip ve atipik gruplar. Pineal
t�m�rler pineasitom, pinealoblastom ve embriyonal formlar olarak
s&#305;n&#305;flan&#305;r. Medulloblastomlar ise n�roektodermal k�kenli oldu&#287;u
d�&#351;�n�len di&#287;er t�m�rlerle (n�roblastom, retinoblastom ve
ependimoblastom) birlikte tekrar s&#305;n&#305;flanm&#305;&#351;t&#305;r.
Kranyal ve periferik sinirlerin t�m�rleri ise 3 grupta ele al&#305;n&#305;r:
Schwannom, n�rofibrom ve n�rofibrosarkom. B�t�n bu say&#305;lanlar&#305;n
d&#305;&#351;&#305;nda ayr&#305; ele al&#305;nan pek �ok t�m�r daha
vard&#305;r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>Tablo 1. Eri&#351;kinlerde Primer MSS T�m�rlerinin
Da&#287;&#305;l&#305;m&#305;</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> (</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Kaynak 2 ve 25�ten
de&#287;i&#351;tirilerek adapte edildi)</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:#FFFFCC;mso-padding-alt:
 0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:black;
  mso-ansi-language:TR'>T�m�r Tipi</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:black;
  mso-ansi-language:TR'>S&#305;kl&#305;k</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:black;
  mso-ansi-language:TR'>Ya&#351;</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:black;
  mso-ansi-language:TR'>5 y&#305;ll&#305;k sa&#287;kal&#305;m</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:#000099;
  mso-ansi-language:TR'>Gliomlar&nbsp;</span></b></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 50</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Glioblastoma multiforme</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 20&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>62&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 6</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Astrositom&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 10&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>50-55</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 20-30</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Ependimom&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 6</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>25</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 50</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Oligodendrositom&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 5</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;43</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 61</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Medulloblastom</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 4</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>S&#305;n&#305;flanamayan gliom&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 5</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:black;
  mso-ansi-language:TR'>Meningiom</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 15</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;61</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 91</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Hipofiz adenomu</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 7</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>N�rinom (Schwannoma)</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><br>
  &nbsp;% 7&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>52 %&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>96</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Kranyofaringiom, teratom,dermoid, epidermoid t</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 4</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Anjiomlar</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 4</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Sarkomlar</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 4</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Di&#287;er (pinealom, kordom, vs)</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 3</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Lenfoma</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 1.5- 15*</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p style='margin-bottom:12.0pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>*Kaynak al&#305;nan yay&#305;n&#305;n y&#305;l&#305; ile
de&#287;i&#351;mektedir. Yak&#305;n tarihli yay&#305;nlarda
s&#305;kl&#305;&#287;&#305;n&#305;n �ok artt&#305;&#287;&#305; dikkati
�ekmektedir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>Tablo 2. �ocuklarda MSS T�m�rlerinin Da&#287;&#305;l&#305;m&#305; </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(Kaynak
2, 23 ve 25�ten adapte edildi)</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellpadding=0 width="84%"
 style='width:84.56%;mso-cellspacing:1.5pt;margin-left:-4.2pt;background:#FFFFCC;
 mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width="88%" style='width:88.34%;background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>T�m�r tipi&nbsp;</span></b></p>
  </td>
  <td width="10%" style='width:10.52%;background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>S&#305;kl&#305;&#287;&#305;</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width="88%" style='width:88.34%;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Gliomlar </span></p>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l0 level1 lfo6;tab-stops:list 36.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
       TR'>Astrositom</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
       TR'> </span></li>
   <li class=MsoNormal style='mso-list:l0 level1 lfo6;tab-stops:list 36.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
       TR'>Medulloblastom</span><span lang=TR style='font-family:Tahoma;
       mso-ansi-language:TR'> </span></li>
   <li class=MsoNormal style='mso-list:l0 level1 lfo6;tab-stops:list 36.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
       TR'>Ependimom</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
       TR'> </span></li>
  </ul>
  </td>
  <td width="10%" style='width:10.52%;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;&gt;% 80&nbsp; <br>
  &nbsp;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'> % 55&nbsp;</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp; % 20&nbsp;</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp; % 8</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width="88%" style='width:88.34%;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Kranyofaringiom&nbsp;</span></p>
  </td>
  <td width="10%" style='width:10.52%;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp; % 5</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;mso-yfti-lastrow:yes'>
  <td width="88%" style='width:88.34%;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Di&#287;er (germ h�c. t., pineal t., koroid pl t.,ilkel n�roektodermal
  t., vb.)&nbsp;</span></p>
  </td>
  <td width="10%" style='width:10.52%;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp; % 12</span></p>
  </td>
 </tr>
</table>

</div>

<p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Patogenez</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> </span></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Primer beyin t�m�rlerinin patogenezi tart&#305;&#351;&#305;l&#305;rken
ba&#351;l&#305;ca iki ana hipotez �zerinde durulur. Bunlardan 1800�l�
y&#305;llardan bu yana �ne s�r�len ilki; beyin t�m�rlerinin embriyonel
kal&#305;nt&#305;lardan ve k�k h�crelerin diferansiyasyon s&#305;ras&#305;nda
blastik de&#287;i&#351;im g�stermesinden kaynakland&#305;&#287;&#305;n&#305;
savunan hipotezdir. Bug�n daha fazla kabul g�ren di&#287;er hipotez ise
olgunla&#351;m&#305;&#351; eri&#351;kin h�crelerin ard&#305;l mutasyonlar
sonucunda kontrols�z proliferasyonu ve dediferansiyasyonu hipotezidir. Son
y&#305;llarda bu ikinci hipotezi do&#287;rulayan pek �ok onkogen ve t�m�r
bask&#305;lay&#305;c&#305; gen tan&#305;mlanm&#305;&#351;t&#305;r. T�m�r
bask&#305;lay&#305;c&#305; genlerden en �nemlisi 17. kromozomdaki P53 genidir.
P53 geni h�cre siklusunun d�zenlenmesinde, DNA hasar&#305;na cevapta ve
programlanm&#305;&#351; h�cre �l�m�nde (apoptoz) �nemli rol oynar. Normal
i&#351;lev g�steren P53 geninin glioblastom h�cre serilerini
bask&#305;lad&#305;&#287;&#305;, mutant P53 geninin ise transformasyon g�steren
astrositlerin �l�ms�zle&#351;mesinde rol oynad&#305;&#287;&#305;
g�sterilmi&#351;tir. P53 geninin �al&#305;&#351;mas&#305;n&#305; d�zenleyen
ba&#351;ka genler de mevcuttur: bunlardan 12. kromozomda bulunan MDM2 geni P53
geninin i&#351;levini bask&#305;lar. Yine, 6. kromozomda yer alan sikline
ba&#287;&#305;ml&#305; kinaz (CDK) genleri taraf&#305;ndan kodlanan P21
proteini h�cre siklusunu durdurur. Bunlar d&#305;&#351;&#305;nda h�cre siklusu
�zerine etkili proteinleri kodlayan bir�ok ba&#351;ka gen de tan&#305;mlanm&#305;&#351;t&#305;r.
Neoplazi olu&#351;umunda h�cre siklusu �zerinde etkili genlerin
d&#305;&#351;&#305;nda, b�y�me fakt�rlerinin ve resept�rlerinin de rol�
vard&#305;r. Bunlar aras&#305;nda epidermal b�y�me fakt�r� (EGF) ve resept�r�
(EGFR), trombosit kaynakl&#305; b�y�me fakt�r� (PDGF) ve resept�r� (PDGFR),
fibroblast b�y�me fakt�r� (FGF) ve damar endotel b�y�me fakt�r� (VEGF)
say&#305;labilir. H�cre geli&#351;iminde rol oynayan bu b�y�me fakt�rlerinin
anormal derecede artmas&#305; h�cre i�i sinyal iletimi ile mitozu
artt&#305;rmaktad&#305;r. T�m�rlerde genellikle hem b�y�me fakt�rlerini hem de
resept�rlerini kodlayan genlerde art&#305;&#351; oldu&#287;u g�zlenmektedir.
Bunlar&#305;n d&#305;&#351;&#305;nda hen�z geni ve kodlad&#305;&#287;&#305;
proteini belirlenmemi&#351; baz&#305; kromozom bozukluklar&#305; da
tan&#305;mlanm&#305;&#351;t&#305;r. B�t�n bu say&#305;lanlardan ba&#351;ka
apoptozun neoplazi geli&#351;imindeki rol� de ortaya konmu&#351;tur. Apoptozda
rol oynayan ba&#351;l&#305;ca iki yol vard&#305;r: birincisi h�cre y�zeyinde
bulunan FAS molek�l� ve buna kar&#351;&#305; gelen FAS ligand&#305; (FASL),
ikincisi de h�cre i�inde bulunan BAX ve BCL-2 proteinleri. FAS ve BAX apoptozu
ind�klerken BCL-2 apoptozu �nler. Daha �nce s�z� edilen P 53 proteini de FAS ve
BAX aktivasyonu yaparken, BCL-2�yi bask&#305;lar. Apoptoz yetene&#287;inin
kayb&#305; hem neoplazi geli&#351;imini ind�kler, hem de tedaviye diren�
sa&#287;lar. Bu nedenle pro-apoptotik proteinlerin artt&#305;r&#305;lmas&#305;
yak&#305;n gelecekte birincil tedavi hedeflerindan biri haline gelebilir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Bu molek�ler genetik bilgilerin &#305;&#351;&#305;&#287;&#305;nda
viruslar&#305;n h�cre i�ine onkogenleri ta&#351;&#305;yarak t�m�r
geli&#351;iminde �nemli rol� olabilece&#287;i d�&#351;�n�lmektedir.
Ebstein-Barr virusu ile lenfoma aras&#305;ndaki ili&#351;ki bilinmektedir.
Primer beyin t�m�rlerinde direkt kan&#305;t olmamakla birlikte Ebstein-Barr
virusu, hepatit-B virusu, insan papilloma virusu ve insan T-lenfosit virusu
gibi ajanlar su�lanmaktad&#305;r. Ancak b�yle bir ili&#351;ki hen�z
kan&#305;tlanmam&#305;&#351;t&#305;r. Bunun d&#305;&#351;&#305;nda kranyal
&#305;&#351;&#305;nlaman&#305;n hem meningiom hem de glial t�m�rlerin
geli&#351;me riskini artt&#305;rd&#305;&#287;&#305; g�sterilmi&#351;tir.
Ayr&#305;ca, petrokimya �r�nleri ve elektromanyetik dalgalar&#305;n beyin
t�m�r� riskini artt&#305;rd&#305;&#287;&#305; ileri s�r�lm�&#351;se de bunun
aksini g�steren �al&#305;&#351;malar da mevcuttur. �zellikle son y&#305;llarda
yayg&#305;n olarak kullan&#305;lan cep telefonlar&#305;n&#305;n etkisi
tart&#305;&#351;&#305;lmaktad&#305;r. Cep telefonu kullan&#305;m&#305; ile
baz&#305; beyin t�m�rlerinin s&#305;kl&#305;&#287;&#305;nda art&#305;&#351;
olabilece&#287;ini d�&#351;�nd�ren baz&#305; �al&#305;&#351;malar mevcuttur.
Ancak, 9 de&#287;i&#351;ik olgu-kontrol �al&#305;&#351;mas&#305;n&#305;n
meta-analizinde bug�n i�in b�yle bir risk olmad&#305;&#287;&#305;
g�sterilmi&#351;tir, uzun vadedeki etkileri zaman i�inde tam olarak
netle&#351;ecektir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Gliomlar</span></b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'> </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>D�&#351;�k
gradl&#305; diff�z astrositomlar: </span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>WHO
s&#305;n&#305;flamas&#305;na g�re grad 2 d�zeyindeki astrositik t�m�rler bu
gruba girer. Y�ksek differansiyasyon g�sterir, sadece n�kleer atipi
vard&#305;r, yava&#351; b�y�r ancak �evre dokulara yayg&#305;n infiltrasyon
g�sterir. Genellikle 30-40 ya&#351; aras&#305; gen� eri&#351;kinlerde
s&#305;kt&#305;r. Yerle&#351;im s&#305;kl&#305;&#287;&#305;
a�&#305;s&#305;ndan, supratentoriyal b�lge birinci, beyinsap&#305; ise ikinci
s&#305;ray&#305; al&#305;r. N�roradyolojik olarak genellikle
s&#305;n&#305;rlar&#305; belirsiz, solid, pek kontrast tutmayan bir kitle
olarak g�r�l�r. BT�de hipodens, MRG�de T1 a&#287;&#305;rl&#305;kl&#305;
kesitlerde hipointens, T2 a&#287;&#305;rl&#305;kl&#305; kesitlerde hiperintens
g�r�n�r. Tedavi, t�m�r yerle&#351;imi riskli degilse, t�m�r�n cerrahi olarak
�&#305;kar&#305;lmas&#305; &#351;eklindedir; m�mk�n oldu&#287;unca geni&#351;
total rezeksiyon hedeflenir. Ek olarak radyoterapinin gereklili&#287;i
tart&#305;&#351;mal&#305; bir konudur; cerrahi olarak ula&#351;&#305;lmas&#305;
g�� olan t�m�rlerde veya radyolojik olarak t�m�r n�ks� veya progresyonu
saptanmas&#305; halinde mutlaka uygulan&#305;r. D�&#351;�k gradl&#305;
astrositomlarda kemoterapinin yerinin olmad&#305;&#287;&#305; d�&#351;�n�l�rd�,
ancak son y&#305;llarda �zellikle �ocuklarda veya geni&#351; t�m�rlerde yeri
olabilece&#287;i g�sterilmi&#351;tir. Cerrahi sonras&#305;nda ortalama
sa&#287;kal&#305;m s�resi 6-8 y&#305;ld&#305;r. Bazen zaman i�inde daha habis
formlara d�n�&#351;�m g�r�lebilir. Bu d�n�&#351;�mde P53 genindeki
mutasyonlar&#305;n rol oynad&#305;&#287;&#305; d�&#351;�n�lmektedir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Anaplastik
astrositom:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> WHO s&#305;n&#305;flamas&#305;na g�re grad 3 d�zeyindeki astrositik
t�m�rler bu gruba girer. �Malign� astrositom veya y�ksek gradl&#305; astrositom
ad&#305; da verilir. Fokal veya yayg&#305;n anaplazinin yan&#305; s&#305;ra,
yo&#287;un proliferasyon ve �evre dokulara yayg&#305;n infiltrasyon g�sterir.
Ba&#351;lang&#305;� ya&#351;&#305; d�&#351;�k gradl&#305; astrositomlara oranla
daha ge�tir (ortalama 41 ya&#351;) ve daha h&#305;zl&#305; ilerler. Genellikle
serebral hemisferlerde yerle&#351;im g�sterir. N�roradyolojik olarak
s&#305;n&#305;rlar&#305; belirsiz, solid bir kitle olarak g�r�l�r. BT�de
hipodens, MRG�de T1 a&#287;&#305;rl&#305;kl&#305; kesitlerde hipointens, T2
a&#287;&#305;rl&#305;kl&#305; kesitlerde hiperintens g�r�n�r. D�&#351;�k
gradl&#305; astrositomlar&#305;n tersine k&#305;smen kontrast tutulumu
vard&#305;r ve �dem etkisi daha belirgindir. Tedavi y�z g�ld�r�c� olmamakla
birlikte 40 ya&#351; alt&#305; gen� hastalarda 1.5 y&#305;ll&#305;k
sa&#287;kal&#305;m oran&#305; % 60 civar&#305;ndad&#305;r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Glioblastoma
multiforme:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> En �malign� astrositik t�m�rd�r (WHO s&#305;n&#305;flamas&#305;na g�re
grad 4). �ok az differansiyasyon g�sterir, yo&#287;un mitoz, damar
proliferasyonu ve nekroz i�erir, �evre dokulara yo&#287;un infiltrasyon
vard&#305;r. Eri&#351;kinlerde en s&#305;k g�r�len beyin t�m�r�d�r. Genellikle
45-70 ya&#351; aras&#305; eri&#351;kinlerde s&#305;kt&#305;r (ortalama 53
ya&#351;), ancak daha gen�lerde de g�r�lebilir. H&#305;zl&#305; ilerler.
Genellikle supratentoriyal yerle&#351;im g�sterir; frontotemporal veya
pariyetal yerle&#351;im s&#305;kt&#305;r; bazal ganglia b�lgesine ve korpus
kallosumdan kar&#351;&#305; hemisfere ge�i&#351; s&#305;kt&#305;r; buna kelebek
gliomu ad&#305; da verilir. Makroskopik veya mikroskopik olarak multifokal
olabilir. N�roradyolojik olarak d�zensiz s&#305;n&#305;rl&#305;, ortas&#305;nda
nekrotik kavite bulunan, �evresinde halkasal d�zensiz kontrast tutulumu
g�steren bir kitle olarak g�r�l�r. Etraf&#305; �demlidir. Bazen BOS�ta protein
art&#305;&#351;&#305;na ve lenfositik pleositoza yol a�abilir. Nadiren de
meningial gliomatosis g�r�lebilir. MSS d&#305;&#351;&#305;na yay&#305;l&#305;m
�ok nadirdir. Prognozu k�t�d�r; 1 y&#305;ll&#305;k sa&#287;kal&#305;m
oran&#305; % 20, 2 y&#305;ll&#305;k sa&#287;kal&#305;m ise % 10
civar&#305;ndad&#305;r. T�m�r�n tamam&#305;n&#305;n cerrahi olarak
�&#305;kar&#305;lmas&#305; genellikle m�mk�n olmamaktad&#305;r, ancak kitlenin
azalt&#305;lmas&#305; a�&#305;s&#305;ndan yararl&#305;d&#305;r. Ek olarak
radyoterapi ve kemoterapi yap&#305;l&#305;r. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>�zellikle t�m�r� b�y�k oranda �&#305;kar&#305;labilmi&#351;, gen� ve genel
durumu iyi hastalarda oral temozolamid ile kemoterapi sa&#287;kal&#305;m
&#351;ans&#305;n&#305; artt&#305;rabilir. Son y&#305;llarda
O-metilguanin-DNA-metil transferaz (MGMT) geni promoter b�lgesinin
metillenmi&#351; olmas&#305;n&#305;n temozolamid ve radyoterapiye cevab&#305;
�nemli oranda artt&#305;rd&#305;&#287;&#305;na dair veriler elde
edilmi&#351;tir. Radyoaktif/kemoterap�tik implantlar ve stereotaktik radyocerrahi
de denenmektedir. Bunlar&#305;n d&#305;&#351;&#305;nda son y&#305;llarda
giderek artan s&#305;kl&#305;kta hedefli biyolojik tedaviler
kullan&#305;lmaktad&#305;r. Y�ksek gradl&#305; glial t�m�rler angiogenik
yap&#305;lar&#305; �ok g��l� t�m�rlerdir. Bu nedenle son y&#305;llarda
yap&#305;lan �al&#305;&#351;malarda �zellikle t�m�r�n yeni damar yapma
potansiyelini hedefleyen yakla&#351;&#305;mlar daha pop�ler olmu&#351;tur.
T�m�r�n yeni damar yapmas&#305;ndan sorumlu temel molek�ller VEFG (�vascular
endothelial growth factor�) ve VEGF resept�rleridir. Klinikte; �evrede bulunan
VEGF�i ba&#287;layarak etkinli&#287;ini azaltan humanize monoklonal antikor
bevacizumab ve VEGFR 1 ve 2�yi bloke eden resept�r tirozin kinaz inhibit�rleri
(sorafenib ve sunatinib) bulunmaktad&#305;r. Bu tedavilerde hedef t�m�r h�cresi
de&#287;il t�m�r�n mikro �evresidir. Bu ajanlar&#305;n kemoterapi ila�lar&#305;n&#305;n
dokuya penetrasyonlar&#305;n&#305; artt&#305;rd&#305;&#287;&#305; da
g�sterilmi&#351;tir ve bevacizumab glioblastoma multiforme tedavisinde FDA
onay&#305; alm&#305;&#351;t&#305;r. Y�ksek gradl&#305; glial t�m�rlerde
hedeflenen di&#287;er genetik yollar aras&#305;nda EGFR (�epidermal growth
factor�), mTOR, P 53, PI3K say&#305;labilir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Pilositik
astrositom:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> D�&#351;�k gradl&#305; astrositomlar aras&#305;ndad&#305;r (WHO grade 1),
ancak �ok net s&#305;n&#305;rlar&#305;n&#305;n olmas&#305; nedeniyle
farkl&#305; kategoride ele al&#305;n&#305;r. Genellikle kistik komponenti
vard&#305;r. �o&#287;unlukla ilk iki ony&#305;lda olmak �zere �ocuklarda ve gen�
eri&#351;kinlerde s&#305;kt&#305;r. MSS�nin pek �ok b�lgesinde g�r�lebilir. En
s&#305;k g�r�ld�&#287;� lokalizasyonlar: optik sinirler (optik sinir gliomu),
optik kiazma-hipotalamus (kiazmatik/ hipotalamik gliom), talamus-bazal ganglia,
serebellum, beyinsap&#305;, serebral hemisferler, daha nadiren de medulla
spinalis olabilir. N�roradyolojik olarak s&#305;n&#305;rlar&#305; belirgin ve
genellikle kontrast tutan bir kitle olarak g�r�l�r. Kistik �zellik g�stermesi
tan&#305;y&#305; kolayla&#351;t&#305;r&#305;r. Yava&#351; b�y�r, bazen stabilize
olabilir hatta gerileyebilir. Malign transformasyon g�stermez. �ok nadiren BOS
yoluyla yay&#305;labilir. Nadiren �l�mc�ld�r. Cerrahi tedavi sonras&#305;nda
serebellar astrositomlu hastalar&#305;n %10�unun 20-30 y&#305;l
ya&#351;ad&#305;&#287;&#305; bildirilmi&#351;tir. Genetik yatk&#305;nl&#305;k
s�z konusu olabilir: Tip 1 n�rofibromatozlu hastalarda en s&#305;k g�r�len MSS
t�m�r�d�r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Oligodendrogliom:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Ba&#351;l&#305;ca
oligodendroglial h�crelere benzeyen h�crelerce olu&#351;turulan diff�z
infiltratif bir t�m�rd�r. WHO s&#305;n&#305;flamas&#305;na g�re grad 2
d�zeyindedir. Grad 3 oldu&#287;unda, yani n�kleer atipi, h�cresel
�e&#351;itlilik ve mitotik aktivite artt&#305;&#287;&#305;nda anaplastik
oligodendrogliom ad&#305;n&#305; al&#305;r; bu durumda bazen vask�ler
proliferasyon ve nekroz da g�sterebilir. Bunlar&#305;n d&#305;&#351;&#305;nda
hem astrositik hem oligodendrositik h�crelerden kaynaklanan oligoastrositomlar
da mevcuttur. Oligodendrogliomlar genellikle 3.- 4. ony&#305;lda g�r�l�rse de
bazen �ocuklarda da g�r�lebilir. Anaplastik oligodendrogliom ise 4.-5.
ony&#305;lda daha s&#305;kt&#305;r. Oligodendrogliomlar s&#305;kl&#305;kla
frontal ve temporal b�lgede derin ak maddede yerle&#351;ir. N�roradyolojik
olarak kitle etkisi olan, BT�de hipo veya izodens g�r�nen, kalsifikasyon
g�sterebilen, MRG�de T1 a&#287;&#305;rl&#305;kl&#305; kesitlerde hipointens, T2
a&#287;&#305;rl&#305;kl&#305; kesitlerde hiperintens g�r�nen ve
s&#305;n&#305;rlar&#305; belirgin olan lezyon g�r�l�r. Hafif kontrast
tutabilir, etraf&#305; �demlidir. Bazen t�m�r i�ine kanama veya kist
bulunabilir. �zellikle anaplastik formda nekrotik kist, kanama, kalsifikasyon
ve kontrast tutulumu daha belirgindir. �ok nadiren oligodendrogliomlar BOS
yoluyla yay&#305;labilir. Tedavide genellikle iyi diferansiye t�m�rlerde cerrahi
yeterlidir; anaplastik olanlarda cerrahinin ard&#305;ndan radyoterapi ve bazen
kemoterapi uygulan&#305;r. Oligodendrogliomda rezeksiyon sonras&#305; ortalama
sa&#287;kal&#305;m yakla&#351;&#305;k 4.5 y&#305;l iken, anaplastik formda
biraz daha k&#305;sad&#305;r. �zellikle kromozom 1p ve 19q alelik kayb&#305; bulunan
t�m�rlerin kemosensitif olmalar&#305; dolay&#305;s&#305;yla t�m�r�n bu y�nden
incelenmesi m�mk�n olursa prognostik �nem ta&#351;&#305;yabilir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Ependimom:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Ventrik�lleri kaplayan
ependimal tabakadan kaynaklanan t�m�rlerdir. WHO s&#305;n&#305;flamas&#305;na
g�re grad 2 olan t�m�rlere ependimom ad&#305; verilir; grad 3 d�zeyindeki, yani
n�kleer atipi, h�cresel �e&#351;itlilik ve artm&#305;&#351; mitotik aktivite
g�steren, bazen vask�ler proliferasyon ve nekroz da i�erebilen t�m�rlere
anaplastik ependimom ad&#305; verilir. Bunlar&#305;n d&#305;&#351;&#305;nda WHO
s&#305;n&#305;flamas&#305;na g�re grad 1 olan iki t�m�r tipi daha vard&#305;r:
subependimom ve sadece kauda-konus b�lgesinde yerle&#351;en miksopapiller
ependimom. Ependimomlar 1 ay-81 ya&#351; aras&#305;nda b�t�n ya&#351;
gruplar&#305;nda g�r�lebilir. Ependimomlar ventrik�llerin herhangi bir b�lgesinde
yer almakla birlikte en s&#305;k 4. ventrik�lden kaynaklan&#305;r. Medulla
spinalisin en s&#305;k rastlanan glial t�m�r� de ependimomdur ve genellikle
lumbosakral b�lgede yer al&#305;r. Bu da&#287;&#305;l&#305;m ya&#351;a g�re
de&#287;i&#351;ir. &#304;nfratentoriyal yerle&#351;im �ocuklarda daha s&#305;k
g�r�l�rken, eri&#351;kinlerde spinal ve infratentoriyal yerle&#351;im e&#351;it
orandad&#305;r. N�roradyolojik g�r�n�m�; s&#305;n&#305;rlar&#305; d�zg�n bir
kitle &#351;eklindedir. Kistik komponenti olabilir, de&#287;i&#351;en oranlarda
kontrast tutabilir. Hidrosefali s&#305;k g�r�l�r. Bazen kom&#351;u normal n�ral
dokuyu infiltre eder. BOS yoluyla, tohumlama (seeding) tipi metastaz
yapmas&#305; s&#305;kt&#305;r. Son iki �zellik anaplastik formda s&#305;k
g�r�l�r. Bazen uzak metastaz dahi g�r�lebilir. Tedavi olarak genellikle t�m�r
rezeksiyonuna ek olarak BOS yoluyla yay&#305;l&#305;ma kar&#351;&#305;
radyoterapi uygulanmaktad&#305;r. Ancak radyoterapi uygulanacak alan&#305;n
geni&#351;li&#287;i tart&#305;&#351;mal&#305;d&#305;r. Anaplastik formda
kemoterapi de eklenebilir. �ocuklarda prognoz k�t� olmakla birlikte spinal
ependimomlarda prognoz olduk�a iyidir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Medulloblastom:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Serebellumda
yerle&#351;en infiltratif ve malign bir ilkel n�roektodermal t�m�rd�r. WHO
s&#305;n&#305;flamas&#305;na g�re grad 4 d�zeyindedir. &#304;lkel
n�roektodermal t�m�rlerin ortak bir �nc� h�creden kaynakland&#305;&#287;&#305;
d�&#351;�n�ld�&#287;�nden farkl&#305; MSS h�cre gruplar&#305;na do&#287;ru
farkl&#305;la&#351;ma g�sterirler. En s&#305;k 7 ya&#351; civar&#305; olmak
�zere genellikle �ocukluk �a&#287;&#305;nda ortaya �&#305;kar ve
hastalar&#305;n ��te ikisi erkektir. �o&#287;unlukla vermiste yerle&#351;im
g�sterir ve 4. ventrik�le uzan&#305;r. N�roradyolojik olarak yo&#287;un ve
homojen kontrast tutulumu g�steren solid kitle &#351;eklinde g�r�l�r.
Leptomeningial yay&#305;l&#305;m s&#305;kt&#305;r ve bu da meninkslerde nod�ler
veya yayg&#305;n kontrast tutulumuna yol a�ar. Tedavide genellikle cerrahinin
ard&#305;ndan radyoterapi uygulan&#305;r. Bu tedavi ile 10 y&#305;ll&#305;k
sa&#287;kal&#305;m oran&#305; yakla&#351;&#305;k % 45 civar&#305;ndad&#305;r,
ancak �ok k���k �ocuklarda radyoterapiden
ka�&#305;n&#305;ld&#305;&#287;&#305;ndan bu olgularda kemoterapi
uygulan&#305;r. Ya&#351;&#305;n k���k olmas&#305;, cerrahi rezeksiyonun tam
olmamas&#305; ve BOS yoluyla yay&#305;l&#305;m bulunmas&#305; k�t� prognoz
i&#351;aretleridir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Meningiom:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Meningiomlar
araknoidal (meningotelyal) h�crelerden kaynaklanan iyi huylu t�m�rlerdir.
Genellikle WHO grad 1 d�zeyindedir; nadiren atipik veya anaplastik meningiom
g�r�lebilir (s&#305;ras&#305; ile WHO grad 2 ve 3). En s&#305;k 6. ve 7.
ony&#305;llarda g�r�l�r. Hastalar&#305;n ��te ikisi kad&#305;nd&#305;r. Ailevi
olgular vard&#305;r. �zellikle tip 2 n�rofibromatozda meningiomlar geli&#351;ir.
Meningiomlar araknoidal k&#305;l&#305;f&#305;n her b�lgesinden kaynaklanabilir.
En s&#305;k falks yerle&#351;imlidir. S&#305;k g�r�ld�&#287;� di&#287;er
b�lgeler olfakt�r yar&#305;k, sfenoid �&#305;k&#305;nt&#305;, parasellar b�lge,
optik sinirler, petroz �&#305;k&#305;nt&#305;, serebellar tentoryum ve arka
�ukurdur. Spinal kanalda en s&#305;k dorsal b�lgede yer al&#305;r. Meningiomlar
�ok yava&#351; b�y�r ve bulundu&#287;u b�lgeye g�re de&#287;i&#351;mekle
birlikte, �ok b�y�medik�e belirti vermeyebilir. N�roradyolojik olarak
kalsifikasyonlar g�steren ve kontrast tutan izodens bir kitle olarak g�r�l�r;
genellikle dura ile birle&#351;ti&#287;i yerde bir �dural kuyruk� bulunur.
Etraf&#305; �demlidir. T�m�r�n cerrahi olarak �&#305;kar&#305;lmas&#305;
kal&#305;c&#305; tedavi sa&#287;lar. Cerrahi giri&#351;imin m�mk�n
olmad&#305;&#287;&#305; hastalarda ve malign meningiomlarda radyoterapi
yap&#305;labilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�roma:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Bu grupta yer alan
Schwannoma ve n�rofibroma WHO s&#305;n&#305;flamas&#305;nda grad 1 d�zeyinde
iyi huylu periferik sinir t�m�rleridir. �ok daha nadir olarak malign
formlar&#305; g�r�lebilir. Bu iki t�m�r tipi de ailevi MSS t�m�r�
sendromlar&#305;nda s&#305;k g�r�len t�m�rlerdir. Birincisi periferik siniri
�evreleyen iyi diferansiye Schwann h�crelerinden olu&#351;ur; ikincisinde ise
Schwann h�crelerinin yan&#305; s&#305;ra, perin�ral-benzeri h�creler,
fibroblastlar ve di&#287;er h�creler de bulunur. Schwannomalar 4.-6.
ony&#305;llar aras&#305;nda s&#305;k olmakla beraber her ya&#351; grubunda
g�r�lebilir; n�rofibroma da her ya&#351; grubunda g�r�lebilir. Schwannoma
genellikle ba&#351;-boyun b�lgesindeki ve ekstremitelerin ekstans�r
taraflar&#305;ndaki sinirlerden kaynaklan&#305;r. Spinal k�klerde ve kranyal
sinirlerde de s&#305;kt&#305;r. �zellikle VIII. kranyal sinirde Schwannoma
s&#305;k g�r�l�r (vestib�ler n�rinom/ akustik n�rinom gibi); bu durumda
serebello-pontin k�&#351;e sendromu bulgular&#305; ortaya �&#305;kar
(Bak&#305;n&#305;z: <span style='color:#4F81BD'><a href="../semi2/cranial.htm">Kranyal
sinirler: k&#305;sa anatomi-fizyoloji, muayene ve bozukluklar&#305;,</a></span>
<span style='color:#4F81BD'><a
href="../kranyalnoropatiler/Kranyalnoropatiler.html">Kranyal N�ropatiler</a></span>
). N�rofibroma ise kranyal sinirlerde g�r�lmez. Genellikle bir cilt nod�l�
&#351;eklindedir, bazen cilt ve ciltalt&#305;n&#305; yayg&#305;n olarak tutar
ve b�t�n ekstremitenin b�y�k g�r�nmesine yol a�ar (elephantiasis neuromatosa).
Kranyal sinirlere ait Schwannoma MRG�de d�zg�n s&#305;n&#305;rl&#305;, bazen
kistik komponentli, kemikte erozyon yapm&#305;&#351; bir kitle olarak g�r�l�r;
homojen kontrast tutan bu tip t�m�rlerin tedavisi cerrahidir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kranyofaringiom:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> �ocuklarda ve
gen�lerde g�r�len iyi huylu bir epitelyal t�m�rd�r (WHO grad 1). Rathke kesesi
kal&#305;nt&#305;lar&#305;ndan geli&#351;ti&#287;i d�&#351;�n�l�r. Genellikle
suprasellar yerle&#351;imlidir; bazen sella i�ine de uzan&#305;r. Optik kiazma
bas&#305;s&#305;na ba&#287;l&#305; g�rme yak&#305;nmalar&#305; ve endokrin bozukluklarla
kendini g�sterir. Heterojen g�r�n�mde yer yer kistik ve yer yer kalsifikasyonlu
bir t�m�rd�r. Solid k&#305;s&#305;mlar&#305; kontrast tutar. BT�de
kalsifikasyonlar hiperdens g�r�n�r. Kolesterol i�eren bir t�m�r oldu&#287;undan
MRG�de kontrasts&#305;z T1 a&#287;&#305;rl&#305;kl&#305; kesitlerde yer yer
hiperintens g�r�nebilir. Tedavi cerrahidir; ancak her zaman t�m�r�n tamam&#305;
�&#305;kar&#305;lamayabilir. Bu durumda n�ksler s&#305;kt&#305;r. Radyoterapi
yap&#305;labilir, ancak yarar&#305; tart&#305;&#351;mal&#305;d&#305;r. Endokrin
bozuklu&#287;un d�zeltilmesi �nemlidir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Primer Serebral Lenfoma</span></b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Merkezi sinir
sisteminde lenfoma s&#305;kl&#305;kla metastatik olarak g�r�l�r. Ancak daha
seyrek olarak ekstra-n�ral bir odak olmaks&#305;z&#305;n sinir sisteminde
lenfoma geli&#351;ebilir. �nceki y&#305;llarda bu t�m�rlerin retik�loendotelyal
sistemden kaynaklanan histiositik sarkom oldu&#287;u d�&#351;�n�l�rd�; bu
nedenle retikulum h�creli sarkom veya mikrogliom gibi isimler verilmi&#351;ti.
Ancak daha sonra immunhistokimyasal y�ntemlerin geli&#351;mesi ile bu t�m�r�n
asl&#305;nda bir malign, non-Hodgkin lenfoma tipi oldu&#287;u g�r�ld�. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Son
y&#305;llar i�inde g�r�len primer serebral lenfoma
s&#305;kl&#305;&#287;&#305;nda belirgin bir art&#305;&#351; dikkati
�ekmektedir. �rne&#287;in 1970�lerde b�t�n MSS t�m�rleri aras&#305;nda
oran&#305; %1�in alt&#305;nda iken son 30 y&#305;lda
s&#305;kl&#305;&#287;&#305; belirgin olarak artm&#305;&#351;t&#305;r; baz&#305;
merkezlerde g�r�len her 5 veya 6 beyin t�m�r�nden birini bunlar
olu&#351;turmaktad&#305;r. Amerika Birle&#351;ik Devletleri�nde g�r�len b�t�n
primer MSS t�m�rlerinin yakla&#351;&#305;k %3��n� primer MSS lenfomas&#305;
olu&#351;turur; b�t�n non-Hodgkin lenfomalar&#305;n ise yine %2-3��n� oluturur.
MSS lenfomas&#305; insidensinde g�r�len art&#305;&#351;&#305;n �nemli bir
nedeni AIDS�li veya transplantasyon nedeniyle immunsupresif tedavi g�ren ve
di&#287;er nedenlerle immun yetersizli&#287;i olan hastalarda s&#305;k ortaya
�&#305;kmas&#305;d&#305;r. &#304;mmun yetersizli&#287;i olan hastalarda
serebral lenfoman&#305;n etyolojisinde Ebstein Barr virusunun rol oynad&#305;&#287;&#305;
d�&#351;�n�lmektedir. Ancak, son birka� y&#305;ld&#305;r primer MSS
lenfomas&#305; s&#305;kl&#305;&#287;&#305;ndaki art&#305;&#351;&#305;n
duraklad&#305;&#287;&#305; da dikkati �ekmektedir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Primer
serebral lenfomalar&#305;n yakla&#351;&#305;k % 90�&#305; B-lenfosit
k�kenlidir. T-lenfosit k�kenli lenfomalar �ok daha nadirdir. &#304;mmun
yetersizli&#287;i olmayan hastalarda 6.-7. ony&#305;llarda ortaya �&#305;karken
konjenital immun yetersizli&#287;i olan �ocuklarda, 10 ya&#351; civar&#305;nda,
transplantasyon hastalar&#305; ve AIDS�lilerde ise 3. ve 4. ony&#305;lda
s&#305;kt&#305;r. Genelde erkeklerde daha s&#305;k g�r�l�r; AIDS�lilerde ise
lenfomal&#305; hastalar&#305;n % 90�&#305; erkektir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>En s&#305;k
frontal lobda, giderek azalan s&#305;kl&#305;kta temporal, parietal ve
oksipital loblarda, arka �ukurda, bazal ganglia ve periventrik�ler b�lgede
(%10), korpus kallosumda, nadiren de omurilikte yerle&#351;ir. Leptomeningial
yay&#305;l&#305;m % 30-40 olguda g�r�l�r. Primer intra-ok�ler lenfoma
&#351;eklinde g�z tutulumu da g�r�lebilir. T-lenfosit lenfomas&#305; arka
�ukuru, �zellikle serebellumu daha fazla tutar; leptomeningial
yay&#305;l&#305;m da daha s&#305;kt&#305;r. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Uluslararas&#305;
MSS Lenfomas&#305; �al&#305;&#351;ma Grubunun yay&#305;nlad&#305;&#287;&#305;
k&#305;lavuza g�re bu hastalar&#305;n de&#287;erlendirmesinde patolojik
inceleme ve immunfenotiplemenin yan&#305; s&#305;ra, ayr&#305;nt&#305;l&#305;
t&#305;bbi ve n�rolojik muayene, HIV serolojisi, kontrastl&#305; kranyal MR,
g�z muayenesi, serum LDH d�zeyi, toraks-abdomen-pelvis BT incelemesi, kontrendikasyon
yoksa BOS sitolojisi, kemik ili&#287;i aspirasyon biyopsisi ve erkek hastalarda
testis muayene ve ultrasonu yap&#305;lmas&#305; �nerilmektedir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�roradyolojik
bulgular:</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> BT�de hipodens veya izodens, MRG�de hiperintens veya izointens g�r�nen tek
veya multipl lezyonlar g�r�l�r. Genellikle solid olur, nadiren kistiktir.
S&#305;kl&#305;kla yayg&#305;n kontrast tutulumu g�sterir. &#304;mmun
yetersizli&#287;i olan hastalarda halkasal kontrast tutulumu g�r�lebilir. Daha
�ok supratentoriyal yerle&#351;ir, periventrik�ler yerle&#351;im
s&#305;kt&#305;r. Bilateral bazal ganglion b�lgesinde kontrast tutan ayna
g�r�nt�s�n�n patognomonik oldu&#287;u s�ylenir. T�m�r ile normal doku
aras&#305;ndaki s&#305;n&#305;r keskin de&#287;ildir, etraf&#305;ndaki �dem de
di&#287;er t�m�rlerde g�r�lenden daha azd&#305;r. Bazen leptomeningial kontrast
tutulumu g�zlenebilir. Metastatik lenfomalar ise s&#305;kl&#305;kla
leptomeningial tutulum yapar, parenkim lezyonu nadirdir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>BOS:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Primer serebral
lenfomal&#305; olgular&#305;n % 35-60�&#305;nda pleositoz g�r�l�r. Ancak sadece
sitoloji ile hastalar&#305;n sadece % 5 ila 30�una tan&#305; konabilir. Oysa
metastatik lenfomalar s&#305;kl&#305;kla leptomeningial tutulum
yapt&#305;&#287;&#305;ndan BOS sitolojisi % 70-95 oran&#305;nda tan&#305;
koydurucu olabilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Stereotaktik
biyopsi:</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Bug�n tercih edilen tan&#305; y�ntemidir. Ancak biyopsi �ncesinde kitleyi
k���ltme �zellikleri nedeniyle kortikosteroid verilmesinden
ka�&#305;n&#305;lmal&#305;d&#305;r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedavi:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Cerrahi giri&#351;imin
tedavide yeri yoktur. Kortikosteroidler t�m�r h�crelerinin tamamen
kaybolmas&#305;na yol a�abilir. Ancak biyopsi planlan&#305;yorsa, biyopsinin
tan&#305;sal de&#287;erini azaltaca&#287;&#305;ndan, �ncesinde kortikosteroid
verilmemesi gerekti&#287;i unutulmamal&#305;d&#305;r. �nceleri tercih edilen
tedavi kranyal radyoterapi ile kombine edilen metotreksat bazl&#305; intraven�z
kemoterapi idi. Ancak bu tedavinin yol a�abilece&#287;i gecikmi&#351; serebral
toksisite nedeniyle bug�n ya tek ba&#351;&#305;na kemoterapi ya da kemoterapi
ile kombine d�&#351;�k doz kranyal radyoterapi kullan&#305;lmaktad&#305;r. MSS
penetrasyonu �ok y�ksek bir oral alkilleyici ajan olan temezolamid de tek
ba&#351;&#305;na veya bir anti-CD 20 monoklonal antikor olan rituksimab ile
birlikte kullan&#305;labilmektedir. Ayr&#305;ca otolog k�k h�cre nakli ile
birlikte y�ksek doz kemoterapi uygulanmas&#305;n&#305; ara&#351;t&#305;ran
�al&#305;&#351;malar da vard&#305;r. Ancak, bug�ne dek herhangi bir tedavinin
di&#287;erine net olarak �st�nl�&#287;� g�sterilmemi&#351;tir. &#304;mmun
yetmezli&#287;i olan hastalarda ba&#287;&#305;&#351;&#305;kl&#305;k sistemini
g��lendirici yakla&#351;&#305;mlarda bulunulmal&#305;d&#305;r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Prognoz:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Tedaviye cevap
genellikle iyidir, ancak s&#305;kl&#305;kla tekrarlar g�r�l�r. Tedavi
sonras&#305; ortalama sa&#287;kal&#305;m bir y&#305;l&#305; biraz a&#351;ar.
&#304;yi prognoz i&#351;aretleri immun yetersizlik bulunmamas&#305;, tek
intrakranyal lezyon, meningial ve/veya ventrik�ler yay&#305;l&#305;m&#305;n
olmamas&#305;, ya&#351;&#305;n 60�&#305;n alt&#305;nda olmas&#305; ve
hastan&#305;n genel durumunun iyi olmas&#305;d&#305;r. Kemoradyoterapinin veya
tek ba&#351;&#305;na serebral radyoterapinin en �nemli yan etkisi n�rotoksisitesidir;
�zellikle 60 ya&#351;&#305;n �zerindeki hastalarda daha s&#305;k g�r�len bu
durum progresif demans, ataksi ve inkontinans &#351;eklinde g�r�l�r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Di&#287;er T�m�rler</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Daha �nce de belirtildi&#287;i gibi sinir sisteminin g�rece s&#305;k
g�r�len t�m�rleri bu b�l�m�n kapsam&#305; i�ine al&#305;nd&#305;. Ancak
bunlar&#305;n d&#305;&#351;&#305;nda pek �ok farkl&#305; t�m�r vard&#305;r. Bunlar
aras&#305;nda ilkel n�roektodermal t�m�rlerden n�roblastoma, retinoblastoma,
vask�ler k�kenli hemangioblastoma, pineal dokudan kaynaklanan pineoblastoma ve
pineositoma, n�ronal k�kenli n�roblastoma, ganglion�roma, ganglion�roblastoma,
ilkel notokord kal&#305;nt&#305;s&#305;ndan geli&#351;en kordoma, kolloid
kistler, kolesteatoma, karotis bifurkasyonunda yerle&#351;en paraganglioma ve
glomus jugulare t�m�r� ile g�rece s&#305;k g�r�len ve ortaya
�&#305;kard&#305;&#287;&#305; g�rme bozukluklar&#305; ve n�ro-endokrin
bozukluklarla tan&#305;nan ancak n�ro-onkoloji kapsam&#305;
d&#305;&#351;&#305;nda ele al&#305;nmas&#305; gereken hipofiz t�m�rleri
say&#305;labilir. Okur bu konular&#305;n ayr&#305;nt&#305;lar&#305; i�in
n�ro&#351;irurji kitaplar&#305;na ba&#351;vurabilir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Ailesel MSS T�m�rleri</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Eskiden beri
baz&#305; ailelerde t�m�r k�melenmeleri oldu&#287;u biliniyordu. Son
y&#305;llarda molek�ler genetik �al&#305;&#351;malar ile bunlar&#305;n
alt&#305;nda yatan genetik patoloji de ortaya konmu&#351;, bu da genel anlamda
kanser olu&#351;um mekanizmalar&#305;n&#305; daha iyi anlamam&#305;z&#305;
sa&#287;lam&#305;&#351;t&#305;r. T�m� otozomal dominant ge�i&#351; g�steren bu
sendromlar <b>Tablo 3</b>�te s&#305;ralanm&#305;&#351;t&#305;r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�rofibromatosis
Tip I:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Von Recklinghausen hastal&#305;&#287;&#305; olarak da
adland&#305;r&#305;l&#305;r. Tan&#305; i�in &#351;u kriterlerden en az ikisi
bulunmal&#305;d&#305;r: 1) �ap&#305; puberte �ncesinde &gt; 5mm, puberte
sonras&#305;nda &nbsp;&gt; 15 mm olan 6 veya daha fazla �caf� au lait� s�tl�
kahverenginde cilt lekesi; 2) iki veya daha fazla n�rofibroma; 3) aksiller veya
inguinal �illenme; 4) optik sinir gliomu; 5) belirgin bir kemik lezyonu; 6)
birinci dereceden bir akrabada tip I n�rofibromatosis bulunmas&#305;. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�rofibromatosis
Tip II:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Genetik olarak tip I n�rofibromatosisden ayr&#305; bir tablodur ve <i>Von
Recklinghausen hastal&#305;&#287;&#305; olarak adland&#305;r&#305;lmaz.</i>
Tan&#305; kriterleri: 1) bilateral akustik n�rinom (Schwannom); veya<i> </i>2)
birinci dereceden bir akrabada tip II n�rofibromatosis bulunmas&#305;,
art&#305;, ya <i>a)</i> unilateral akustik n�rinom, ya da<i> b) </i>a&#351;a&#287;&#305;dakilerden
ikisi: meningiom, Schwannom, gliom, n�rofibrom, arka subkaps�ler lens
opasitesi, serebral kalsifikasyon; veya 3) a&#351;a&#287;&#305;dakilerden
ikisi: <i>a)</i> unilateral akustik n�rinom;<i> b)</i> multipl meningiom; <i>c)
</i>Schwannom, gliom, n�rofibrom, arka subkaps�ler lens opasitesi, serebral
kalsifikasyon. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp; <br>
&nbsp; </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<b><span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:TR;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always'>
</span></b>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>Tablo 3. Familyal MSS T�m�rleri </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(Kaynak 22�den) </span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp; </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:#FFFFCC;mso-padding-alt:
 0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Sendrom&nbsp;</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;Gen&nbsp;</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Kromozom</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;Sinir sistemi&nbsp;</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Cilt</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;Di&#287;er</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�rofibromatosis I&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>NF1</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>17q11&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>n�rofibromlar, MPNST,optik gliom, astrositom</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;�caf� au lait�,aksiller �iller</span><span
  lang=FR style='mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>iris hamartomu, oss�z,lezyonlar,, l�semi,feokromasitoma</span><span
  lang=FR style='mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�rofibromatosis II</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;NF2&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>22q12&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>bilateral akustik n�rinom, periferik n�rinomlar
  (Schwannom), meningiomlar, spinal ependimomlar, astrositomlar, vs.</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp; (-)</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>arka lens opasitesi, retinal hamartom</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>von Hippel Lindau&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;VHL&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>3p25&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>hemangioblastom&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(-)</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>renal ca., retinal hemangioblastom, feokromasitoma,</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>organ kistleri</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Tuberoz Skleroz</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>TSC1</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>TSC2&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>9q34</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>16p13&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>subependimal dev h�creli astrositom,&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>kortikal �tuber�ler&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>anjiofibromlar</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>�peau chagrin�, subungual&nbsp; fibrom</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>kardiyak rabdomiyom,</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>adenomat�z G&#304;S&nbsp; akci&#287;er-&nbsp; b�brek kistleri, vs.</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Li-Fraumeni&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>TP53</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>17p13&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>astrositomlar, PNET&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;(-)&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>meme ca., l�semi,</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>kemik ve yumu&#351;ak doku</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>sarkomlar&#305;, adrenal korteks ca.</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Cowden&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>PTEN&nbsp;&nbsp; (MMAC1)&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>10q23&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>serebellumda displastik gangliositom</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>tri&#351;ilemmom, fibromlar</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>kolonda hamartomat�z</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>polipler, tiroid tm,&nbsp;</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>meme ca.</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Turcot&nbsp;</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> <br>
  &nbsp; <br>
  &nbsp; </span></p>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>APC</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>hMLH1</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>hPSM2&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>5q21&nbsp;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>3p21&nbsp;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>7p22&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>medulloblastom</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>glioblastoma&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(-)</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>�caf� au lait�</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>kolorektal polipler</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>kolorektal polipler</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nevoid bazal ca. sendromu&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>PTCH</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>9q31</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>medulloblastom</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;multipl bazal ca.</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�ene kistleri, over fibromlar&#305;, iskelet
  anomalileri</span></p>
  </td>
 </tr>
</table>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>MPNST: malign periferik sinir k&#305;l&#305;f t�m�r�, PNET: ilkel
n�roektodermal t�m�r</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p><a name="Sistemik_Kanserin_N�rolojik"></a><b><span lang=TR style='font-size:
14.0pt;font-family:Tahoma;text-transform:uppercase;mso-ansi-language:TR'>Sistemik
Kanserin N�rolojik Etkileri</span></b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma;text-transform:uppercase;mso-ansi-language:TR'> </span></p>

<p style='margin-top:0cm;margin-right:0cm;margin-bottom:12.0pt;margin-left:
0cm'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Sistemik
kanserin n�rolojik komplikasyonlar&#305; n�roloji ile u&#287;ra&#351;an hekimin
g�nl�k prati&#287;inde giderek artan s&#305;kl&#305;kta ve �nemli bir yer
tutmaktad&#305;r. N�fusun ya&#351; ortalamas&#305;n&#305;n artmas&#305;,
end�striyel toksinlere daha fazla maruz kalma gibi nedenlerle kanser insidensi
giderek artmaktad&#305;r. Ayr&#305;ca, yeni tedavi y�ntemlerinin geli&#351;mesi
ile kanserli hastalar&#305;n sa&#287; kal&#305;m s�resi uzamakta, infeksiyon ve
metabolik sorunlarla ba&#351;a �&#305;kmada geli&#351;tirilen yeni y�ntemler de
sa&#287;kal&#305;m �zerinde olumlu etki g�stermektedir. Bunlara ba&#287;l&#305;
olarak zaman i�inde g�r�lebilecek n�rolojik problemler de artmaktad&#305;r.
Ayr&#305;ca kanserli hastalarda g�r�lebilen n�rolojik komplikasyonlar
genellikle acilen m�dahale edilmesi gereken ciddi, ancak tedavi ile k&#305;smen
de olsa rahatlat&#305;lmas&#305; m�mk�n olan sorunlard&#305;r. Bu nedenlerle
n�roloji prati&#287;inde �nemli bir yeri vard&#305;r. Kanserli bir hastada
belirti veren sinir sistemi b�lgesine g�re aranmas&#305; gereken komplikasyon
t�rleri<b> Tablo 4</b>�te verilmektedir. <br>
<a name="Direkt_t�m�r_yay&#305;l&#305;m&#305;na_ba&#287;l&#305;_(metastati"></a><br>
<b><span style='color:black'>Tablo 4. Kanserli hastada belirti veren b�lgeye
g�re aranmas&#305; gereken n�rolojik komplikasyon t�rleri </span></b></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(Kaynak
26�dan).</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:#FFFFCC;mso-padding-alt:
 0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>B�lge</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�rolojik komplikasyon</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Beyin</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Parenkim
       metastaz&#305; </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Leptomeningial
       metastaz </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Metabolik ve
       toksik ensefalopati </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;nfeksiyon
       (menenjit, abse) </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Radyasyon
       ensefalopatisi </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Serebrovask�ler
       olay </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       (limbik ensefalopati, vs.) </span></li>
  </ul>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Omurilik &amp; kauda ekuina</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidural
       bas&#305; </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Leptomeningial
       metastaz </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;ntramed�ller
       metastaz </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidural abse
       veya kanama </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Radyasyon
       miyelopatisi </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;ntratekal
       kemoterapiye ba&#287;l&#305; miyelopati </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       miyelopati </span></li>
  </ul>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Kranyal ve periferik sinir</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>T�m�r veya
       di&#287;er kitlelere ba&#287;l&#305; bas&#305; </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>T�m�r
       taraf&#305;ndan infiltrasyon </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kemoterapi
       toksisitesi </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Varisella zoster
       infeksiyonu </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Radyasyon
       pleksopatisi </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       n�ropati </span></li>
  </ul>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>N�rom�sk�ler bile&#351;ke</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;la�lar
       (aminoglikozid antibiyotikler) </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik bozukluk
       (Lambert-Eaton miyastenik sendromu, miyastenia gravis) </span></li>
  </ul>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Kas</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Steroid
       miyopatisi </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Ka&#351;ektik
       miyopati </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       polimiyozit / dermatomiyozit </span></li>
  </ul>
  </td>
 </tr>
</table>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><br>
</span><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>T�m�r Yay&#305;l&#305;m&#305;na Ba&#287;l&#305; (Metastatik) Etkiler</span></b><span
lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�rolojik
yak&#305;nmalar&#305; olan kanserli hastalar&#305;n yakla&#351;&#305;k
yar&#305;s&#305;nda bu yak&#305;nmalar do&#287;rudan t�m�r invazyonuna
ba&#287;l&#305;d&#305;r. Kanserli hastalar&#305;n yakla&#351;&#305;k % 25�inde
beyin parenkimine, dura veya meninkslere metastaz g�r�l�r; % 5�inde ise spinal
metastaz vard&#305;r. Y&#305;lda 100 000 ki&#351;ilik n�fus ba&#351;&#305;na
MSS metastaz&#305; ile giden hastal&#305;k oran&#305; 4 ile 11 aras&#305;nda
de&#287;i&#351;ir. Beyin metastaz&#305; s&#305;kl&#305;&#287;&#305; ya&#351;la
birlikte artar. Bunlar&#305;n d&#305;&#351;&#305;nda, do&#287;rudan MSS�yi
tutmamakla birlikte kemik metastazlar&#305; da �zellikle medulla spinalis
bas&#305;lar&#305; yaratarak �nemli n�rolojik sorunlara yol a�abilmektedir.
�zetle, <i>kanserli oldu&#287;u bilinen bir hasta n�rolojik tablo
geli&#351;tirdi&#287;i takdirde �ncelikle metastaz
olas&#305;l&#305;&#287;&#305; d�&#351;�n�lmelidir</i>. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>T�m�r�n sinir sistemine ula&#351;mas&#305; �e&#351;itli yollardan olur.
Beyin parenkim metastazlar&#305;nda yay&#305;l&#305;m t�r� hematojendir. Bu yollardan
biri olarak Batson ven�z pleksusundan da s�z etmek gerekir: Batson ven�z
pleksusu olarak bilinen, vertebral ven�z pleksus pelvisten kranyal ven�z
sin�slere uzanan ve kapak�&#305;k i�ermeyen bir sistemdir. Bu sistem
arac&#305;l&#305;&#287;&#305; ile iki y�ne do&#287;ru da hematojen metastazlar
ger�ekle&#351;ebilir. Leptomeningial metastaz ise perin�ral lenfatikler
kanal&#305;yla ya da beyin metastazlar&#305;ndan BOS�a d�k�len h�creler<i> </i>sonucu
olu&#351;ur. Bunlar&#305;n d&#305;&#351;&#305;nda t�m�r�n kendi kitlesinin veya
lenf nodu ya da uzak metastazlar&#305;n&#305;n �evre<i> </i>dokuyu infiltre
etmesi s�z konusu olabilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:13.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Beyin Metastaz&#305;</span></b><span lang=TR style='font-size:13.0pt;
font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Beyin
metastaz&#305;n&#305;n en s&#305;k nedenleri akci&#287;er kanseri, melanom,
meme kanseri, renal kanser ve lenfoma gibi t�m�rler olmakla birlikte,
olgular&#305;n % 10�unda metastaz&#305;n kayna&#287;&#305; belirlenemez.
Di&#287;er yandan, �zellikle s&#305;k beyin metastaz&#305; yapan kanserler
de&#287;erlendirildi&#287;inde: melanomlar&#305;n % 75�i, testis kanserlerinin
% 57�si, akci&#287;er kanserlerinin % 35�i beyin metastaz&#305; yapar. Beyin
dokusuna hemen hi� metastaz yapmayan baz&#305; kanserler de vard&#305;r. Bunlar
aras&#305;nda prostat, �zofagus, orofarinks ve melanom d&#305;&#351;&#305; cilt
kanserleri yer al&#305;r. Buna kar&#351;&#305;n, prostat, meme kanseri, multipl
miyelom ve Hodgkin hastal&#305;&#287;&#305;, non-Hodgkin lenfoma ile birlikte
dural metastaz g�r�l�r. Beyin parenkim metastazlar&#305;n&#305;n % 80�i
hemisferlerde % 20�si arka �ukurda yer al&#305;r; ancak pelvik organlar&#305;n
ve kolon kanserinin metastazlar&#305; arka �ukuru tercih eder. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Beyin
metastazlar&#305; di&#287;er t�m�rler gibi ba&#351;l&#305;ca kafa i�i
bas&#305;n� art&#305;&#351;&#305; sendromu veya epileptik n�betlerle
kar&#351;&#305;m&#305;za �&#305;karlar. Ayr&#305;ca bulunduklar&#305; b�lgeye
�zg� belirtiler de verebilirler. Birden fazla say&#305;da (multipl)
olduklar&#305;nda tan&#305; g��l�&#287;� yarat&#305;rlar. Bazen de
davran&#305;&#351; de&#287;i&#351;ikli&#287;i, uyan&#305;kl&#305;k kusuru ve
silik n�rolojik bulgularla genel bir ensefalopati tablosuna yol a�abilirler. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�roradyoloji:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> BT�de metastazlar
izodens veya hipodens d�zg�n s&#305;n&#305;rl&#305; lezyonlar olarak g�r�l�r.
Yo&#287;un homojen veya �evresel kontrast tutulumu vard&#305;r, etraf&#305;
�demlidir. BT�nin negatif olmas&#305; metastaz olas&#305;l&#305;&#287;&#305;n&#305;
ortadan kald&#305;rmaz, ku&#351;ku varsa MRG yap&#305;lmal&#305;d&#305;r.
Metastazlar MRG�de T1 a&#287;&#305;rl&#305;kl&#305; kesitlerde hipointens, T2
a&#287;&#305;rl&#305;kl&#305; kesitlerde hiperintens g�r�n�r. Belirgin kontrast
tutulumu g�sterir. Metastatik lezyon say&#305;s&#305; da primer t�m�r tipi
hakk&#305;nda bilgi verebilir. Tek lezyon varsa, b�brek, meme, tiroid,
akci&#287;er adenokarsinomu akla gelmelidir. K���k h�creli akci&#287;er kanseri
ve melanom �ok say&#305;da metastaz yapar. Bazen kontrasts&#305;z BT�de
lezyonlarda kanama g�zlenebilir. En s&#305;k kanayan metastazlar melanom,
koryokarsinom, akci&#287;er, renal ve surrenal kanserlerine aittir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Ay&#305;r&#305;c&#305;
tan&#305;:<b> </b></span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Metastatik hastal&#305;&#287;&#305;n
ay&#305;r&#305;c&#305; tan&#305;s&#305;nda primer beyin t�m�rleri, infeksiy�z
lezyonlar, a&#351;a&#287;&#305;da s�z� edilecek olan paraneoplastik sendromlar,
baz&#305; durumlarda demiyelinizan hastal&#305;k akla gelmelidir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedavi:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Akut iyilik hali
sa&#287;lanmas&#305; i�in kortikosteroidler kullan&#305;labilir. Standart
olarak g�nde 16 mg deksametazon ile ba&#351;lanabilir, etki sa&#287;lanmazsa 48
saatte bir doz artt&#305;r&#305;larak 100 mg/g�n dozuna kadar
�&#305;k&#305;labilir. Ancak �ok uzun kullan&#305;mda steroidlerin bilinen
sak&#305;ncalar&#305; g�ndeme gelecektir. Kontrastl&#305; MRG ile
g�sterilmi&#351; tek bir lezyon varsa, primer t�m�r de iyi durumdaysa,
metastaz&#305;n rezeksiyonu d�&#351;�n�lmelidir. Cerrahi giri&#351;imin
ard&#305;ndan da radyoterapi yap&#305;l&#305;r. Sistemik kemoterapinin
baz&#305; durumlar haricinde serebral metastazlara pek etkili
olmad&#305;&#287;&#305; d�&#351;�n�lmektedir. Cerrahi giri&#351;im
yap&#305;lamayan ya da multipl metastazl&#305; hastalarda sadece radyoterapi
uygulanabilir. Radyoterapinin 48-72 saat �ncesinde 16 mg deksametazon veya
e&#351;de&#287;erinin verilmesi akut radyoterapi yan etkilerini �nlemek
a�&#305;s&#305;ndan yararl&#305;d&#305;r. Tedaviye ra&#287;men metastatik beyin
t�m�rlerinin prognozu k�t�d�r. Ortalama sa&#287;kal&#305;m 6 ay
civar&#305;ndad&#305;r. Ancak lenfoma, baz&#305; meme kanserleri,
koryokarsinom, testis kanseri gibi radyasyona duyarl&#305; t�m�rlerde
sa&#287;kal&#305;m daha uzun olabilir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:13.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Spinal Metastaz</span></b><span lang=TR style='font-size:13.0pt;font-family:
Tahoma;mso-ansi-language:TR'> </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kanserli
hastalarda omurili&#287;i ilgilendiren �� tip metastatik lezyon vard&#305;r. En
s&#305;k g�r�len epidural lezyonlard&#305;r. Bunlar&#305;n �o&#287;unlu&#287;u
omurlardaki kemik metastazlar&#305;ndan kaynaklan&#305;r. Ayr&#305;ca
paravertebral yap&#305;lardan ve epidural bo&#351;lukta yer alan metastatik
lezyonlardan da kaynaklanabilir. Bunun d&#305;&#351;&#305;nda tek bir kitle
halinde veya leptomeningial yay&#305;l&#305;m &#351;eklinde intradural
ekstramed�ller yerle&#351;imli ve/veya intramed�ller yerle&#351;imli
metastazlar da g�r�lebilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidural
metastaz:</span></i></b><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Vertebralar,
kemik metastaz&#305;na yol a�an kanserlerde % 70�e varan oranlarda, en �ok
tutulan b�lgelerdir. �o&#287;unlu&#287;u a&#287;r&#305; d&#305;&#351;&#305;nda
asemptomatik kal&#305;r. Bu a&#287;r&#305;, lokal ve &#351;iddetlidir.
Perk�syonla hassasiyet saptan&#305;r. Yakla&#351;&#305;k ��te birlik b�l�m�
epidural bas&#305;ya yol a�abilir. N�rolojik bulgu veren spinal epidural
metastazlar&#305;n yakla&#351;&#305;k % 25�i meme, % 15�i akci&#287;er, % 10�u
prostat kanserine, % 10�u da lenforetik�ler sistem t�m�rlerine aittir.
Yakla&#351;&#305;k % 10-15�inde primer b�lge belirlenemeyebilir. En s&#305;k
dorsal vertebralarda metastaz g�r�l�r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidural metastazlar
ba&#351;l&#305;ca �� mekanizma ile belirti verir. 1) erken d�nemde bas&#305;ya
ba&#287;l&#305; ak maddede �dem ve aksonal &#351;i&#351;me g�r�l�r, bu d�nemde
bas&#305;n&#305;n ortadan kald&#305;r&#305;lmas&#305; ile normal i&#351;lev
kazan&#305;labilir; 2) �zellikle �n ve arkadan bas&#305;da spinal
damarlar&#305;n s&#305;k&#305;&#351;mas&#305; ile medulla spinalis
infarkt&#305; geli&#351;ir; 3) bas&#305;ya ba&#287;l&#305; vazojenik �dem
geli&#351;ir, bu durum steroidlere cevapl&#305;d&#305;r. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�rolojik
aciller kapsam&#305;nda de&#287;erlendirilmesi gereken bu klinik tabloda</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>, a&#287;r&#305; ortaya
�&#305;kan ilk bulgudur. B�lgesel veya radik�ler nitelikte olan a&#287;r&#305;,
zaman i�ersinde olduk�a &#351;iddetli bir nitelik kazan&#305;r. Klinik
ba&#287;lamda; hasta yatar durumdayken &#351;iddetlenir, ki&#351;i otururken
daha rahatt&#305;r. Ard&#305;ndan parestezi gibi duysal yak&#305;nmalar ve
h&#305;zl&#305;ca, tutulan miyotoma �zg�, kas zaaf&#305; geli&#351;ir.
Ayr&#305;ca etkilenen b�lgeye g�re seviye g�steren tam veya k&#305;smi med�ller
sendrom bulgular&#305; bulunabilir (Bak&#305;n&#305;z:Sinir Sistemi
Semiyolojisi). Klasik med�ller sendrom bulgular&#305; d&#305;&#351;&#305;nda
nadiren Lhermitte belirtisi, ps�doklodikasyon, papil�dem, spinal miyokloniler
ve �ok ender olarak �moving toes� g�r�lebilir. Epidural metastaz&#305;n
ay&#305;r&#305;c&#305; tan&#305;s&#305;nda epidural kanama, epidural abse, disk
f&#305;t&#305;kla&#351;mas&#305; ve di&#287;er epidural kitleler akla
gelmelidir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;ntradural
ve intramed�ller metastaz:</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Dura i�erisindeki metastazlar metastatik spinal t�m�rlerin
en az&#305;n&#305;, yakla&#351;&#305;k % 5 kadar&#305;n&#305; olu&#351;turur.
&#304;ntradural ekstramed�ller metastazlar bir sonraki leptomeningial metastaz
ba&#351;l&#305;&#287;&#305; alt&#305;nda incelenecektir. Bu t�r metastazlar
nadiren intradural bir kitle olu&#351;turarak etki edebilirler.
&#304;ntramed�ller metastazlar ise daha �ok hematojen yolla olur. Bazen de
leptomeningial t�m�r omurili&#287;i infiltre eder. Sonu�ta olduk�a nadir bir
durumdur. &#304;ntramed�ller metastaz&#305;n en s&#305;k nedenleri;
akci&#287;er t�m�rleri (yakla&#351;&#305;k % 50), meme kanseri ve Hodgkin,
Hodgkin-d&#305;&#351;&#305; lenfomalard&#305;r. Klini&#287;i, a&#287;r&#305;
daha geri planda olmak �zere epidural bas&#305; gibidir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�roradyoloji:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Gerek epidural
bas&#305;, gerekse intramed�ler metastaz ku&#351;kusu olan durumlarda en uygun
inceleme y�ntemi kontrasts&#305;z ve kontrastl&#305; spinal MRG�dir. Kemik
metastaz&#305;na ba&#287;l&#305; epidural bas&#305;larda direkt radyografiler
bile olgular&#305;n % 75�inden fazlas&#305;nda sorumlu lezyonu g�sterebilir. Bu
durumda kemik sintigrafisi yararl&#305; olabilir. Bas&#305;n&#305;n d�zeyini
belirlemek i�in �nceki y&#305;llarda miyelografi ve intratekal kontrastl&#305;
BT �ekilirdi. Ancak, MRG sonras&#305; bu y�ntemler nadiren
uygulanmaktad&#305;r. MRG pek �ok farkl&#305; olas&#305;l&#305;&#287;&#305;n
ay&#305;rdedilmesinde yararl&#305;d&#305;r. �zellikle intramed�ller
metastazlar&#305;n g�r�lmesini sa&#287;lar. &#304;ntramed�ller metastazlar
MRG�de solid, s&#305;n&#305;rlar&#305; belirgin kitle &#351;eklinde g�r�l�r.
Genellikle T1�de hipointens, T2�de hiperintenstir ve yo&#287;un kontrast
tutulumu g�sterir. &#304;ntramed�ller metastazlar&#305;n radyolojik
ay&#305;r&#305;c&#305; tan&#305;s&#305;na primer med�ller t�m�rler, radyasyon
miyelopatisi, vask�ler omurilik hastal&#305;&#287;&#305;, paraneoplastik
miyelopati ve demiyelinizan miyelopati girebilir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedavi:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Epidural metastaz
bas&#305;s&#305; �ok acil bir durumdur. Bug�n yayg&#305;n kabul g�ren tedavi
&#351;ekli acil radyoterapi veya cerrahi dekompresyon sonras&#305;nda
radyoterapi yap&#305;lmas&#305;d&#305;r. Ancak epidural bas&#305; saptan&#305;r
saptanmaz di&#287;er tedavi se�enekleri ger�ekle&#351;tirilene kadar beklemeden
hemen y�ksek doz steroid (100 mg deksametazon veya 1000 mg metil prednizolon)
yap&#305;lmas&#305; gereklidir. &#304;ntramed�ller metastazlar&#305;n
tedavisinde genellikle steroidler ve radyoterapi yer al&#305;r. Metastazektomi
�ok nadir durumlarda d�&#351;�n�lebilir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Leptomeningial
Metastaz</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> : Meninkslerin malign h�creler taraf&#305;ndan infiltre edilmesi
leptomeningial metastaz olarak adland&#305;r&#305;l&#305;r. Bu h�creler l�semik
h�crelerse bu duruma meningial l�semi (veya l�semik menenjit), kanser h�creleri
ise meningial karsinomatoz (veya karsinomatoz menenjit) ad&#305; verilir.
Kanserli hastalarda leptomeningial metastaz s&#305;kl&#305;&#287;&#305; tam
olarak bilinmemekle beraber primer neoplazinin niteli&#287;ine g�re
de&#287;i&#351;kenlik g�sterir. Solid t�m�rl� hastalar&#305;n
yakla&#351;&#305;k %5�inde g�r�l�rken hematolojik neoplazili hastalarda
(l�semi, lenfoma) bu oran %5-15 aras&#305;nda olabilir. Ancak, bir otopsi
�al&#305;&#351;mas&#305;nda n�rolojik bulgu veren kanserli olgular&#305;n
%19�unda saptanm&#305;&#351; olmas&#305;, muhtemelen hastalar&#305;n bir
k&#305;sm&#305;nda g�zden ka�abildi&#287;ini d�&#351;�nd�rmektedir.
Leptomeningial metastaz yapabilen di&#287;er t�m�rler meme kanseri, k���k
h�creli akci&#287;er kanseri, melanom ile non-Hodgkin lenfoma, akut lenfositik
ve non-lenfositik l�semi gibi hematolojik t�m�rlerdir. Leptomeningial metastaz
genellikle ge� d�nemde, yayg&#305;n hastal&#305;kla birlikte ortaya �&#305;kar.
�ok daha seyrek olarak birka� y&#305;l&#305; bulan hastal&#305;ks&#305;z
d�nemin ard&#305;ndan ortaya �&#305;kabilir. Bazen de sistemik kanserin ilk
belirtisini olu&#351;turdu&#287;undan klinik tan&#305;y&#305; koymak son derece
�nemlidir. Primeri bilinmeyen karsinomatoz menenjit, olgular&#305;n
yakla&#351;&#305;k %5�ini olu&#351;turmaktad&#305;r. T�m�rlerde
sa&#287;kal&#305;m&#305;n&#305;n artmas&#305; ile orant&#305;l&#305; olarak
insidensi artar. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Leptomeningial
metastazlar genellikle multifokal belirti ve bulgular verir. BOS
dolan&#305;m&#305;n&#305; bozarak kafa i�i bas&#305;n� art&#305;&#351;&#305;
sendromuna yol a�ar; damarlar&#305;n parenkim i�ine girdi&#287;i Virchow-Robin
aral&#305;klar&#305;n&#305; izleyerek parenkim invazyonu yapar ve epileptik
n�betlere veya genel bir ensefalopati tablosuna yol a�ar; yine Virchow-Robin
aral&#305;klar&#305;na yay&#305;lm&#305;&#351; t�m�r h�creleri burada yer alan
damarlardaki ak&#305;m&#305; bozarak iskemiye neden olur. B�t�n bunlara
ba&#287;l&#305; olarak hastalarda �� ana grupta belirtiler ortaya
�&#305;kabilir: serebral hemisferik tutuluma ba&#287;l&#305;
ba&#351;a&#287;r&#305;s&#305; olabilir, mental de&#287;i&#351;iklik
g�r�lebilir, bulant&#305;-kusma olur, dengesizlik ve y�r�me g��l�&#287;�
olabilir. Diabetes insipidus g�r�lebilir. &#304;kinci grup bulgu multipl
kranyal sinir tutulumuna ait bulgulard&#305;r; ���nc� grupta da poliradik�ler
tutuluma ba&#287;l&#305; radik�ler a&#287;r&#305; ve asimetrik refleks
kayb&#305; say&#305;labilir. Seyrek olarak meningial iritasyon bulgular&#305;
saptanabilir. �zetle; merkezi sinir sistemine ili&#351;kin farkl&#305;, birka�
anatomik lokalizasyon bulgusu saptanan hastalarda bu tan&#305;
olas&#305;l&#305;&#287;&#305; kuvvetle d�&#351;�n�lmeli ve acilen tan&#305;
koydurucu incelemeler yap&#305;lmal&#305;d&#305;r. �nceden de s�z�
edildi&#287;i gibi, sistemik kanseri bilinmeyen bir hasta meningial tutuluma
ba&#287;l&#305; n�rolojik tablo nedeniyle �ncelikle n�rolo&#287;a
ba&#351;vuracakt&#305;r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tan&#305;:</span></i><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Meningial tutulum
tan&#305;s&#305; BOS incelemesinde malign h�cre g�r�lmesi ile konur. Ancak
n�rolojik bulgular&#305; olan bir kanser hastas&#305;nda BOS incelemesinden
�nce yer kaplayan bir kitleyi d&#305;&#351;lamak i�in kranyal ve spinal MRG
yap&#305;lmal&#305;d&#305;r. MRG s&#305;ras&#305;nda kontrast madde verilirse
meninkslerde da&#287;&#305;n&#305;k lineer veya nod�ler kontrast tutulumu g�zlenebilir.
Yer kaplay&#305;c&#305; kitleyi d&#305;&#351;laman&#305;n yan&#305; s&#305;ra,
bazen lomber ponksiyon sonras&#305;nda meningial kontrast tutulumu
g�r�lebilece&#287;inden, BOS incelemesinin MR sonras&#305;nda
yap&#305;lmas&#305; daha do&#287;ru olacakt&#305;r. Gerekli BOS incelemeleri
aras&#305;nda bas&#305;n� �l��m�, h�cre say&#305;m&#305;, protein ve &#351;eker
d�zeyi �l��m�, sitolojik inceleme yer al&#305;r. &#304;nfeksiyon ku&#351;kusu
varsa buna y�nelik incelemeler de yap&#305;lmal&#305;d&#305;r. BOS�ta
genellikle birka� h�creden birka� y�z h�creye kadar de&#287;i&#351;ebilen bir
lenfositik pleositozun yan&#305; s&#305;ra malign h�creler de g�r�l�r. Protein
d�zeyi artm&#305;&#351;t&#305;r, immunglobulin d�zeyleri de artabilir.
&#304;ntratekal immunglobulin sentezini g�steren oligoklonal bantlar
saptanabilir. Buna kar&#351;&#305;n, s&#305;k g�r�lmese de BOS &#351;ekerinin
azalmas&#305; �nemli bir bulgudur. Leptomeningial metastaz tan&#305;s&#305;nda BOS
incelemesinin en �nemli k&#305;sm&#305; sitolojidir. Sitoloji
laboratuvar&#305;na en az 4 ml BOS g�nderilmelidir. BOS�un bekletilmeden
g�nderilmesi �ok �nemlidir. �ok �nerilmemekle birlikte, laboratuvara hemen
ula&#351;mayacaksa BOS al&#305;n&#305;r al&#305;nmaz e&#351;it miktarda saf
alkol eklenerek fikse edilmesi denenebilir. &#304;lk BOS incelemesinde pozitif
sitolojik sonu� elde etme &#351;ans&#305; % 50 civar&#305;ndad&#305;r; bu oran
ikinci incelemede % 80�i bulur. E&#287;er ilk al&#305;nan BOS�ta malign h�cre
saptanamazsa, inceleme bir kere daha yinelenmelidir. Hala negatifse, ancak
klinik ku&#351;ku g��l�yse ���nc� kez de al&#305;nabilir. M�mk�nse rutin
sitolojik incelemenin yan&#305; s&#305;ra immunhistokimyasal
�al&#305;&#351;malar ve y�zey belirteci �al&#305;&#351;malar&#305; da
yap&#305;lmal&#305;d&#305;r. Bunlar&#305;n d&#305;&#351;&#305;nda BOS�ta t�m�r
belirte�leri (karsinoembriyojenik antijen, alfa-fetoprotein, beta-koryonik
gonadotropin) kandaki konsantrasyonlardan �ok daha y�ksek konsantrasyonda
bulunursa �zellikle primer t�m�r hakk&#305;nda ipucu vermesi
bak&#305;m&#305;ndan yararl&#305; olabilir. Baz&#305; durumlarda, �zellikle
kauda ekuina sendromu s�z konusu ise, BOS al&#305;n&#305;rken intratekal
kontrast madde verilerek miyelografi yap&#305;labilir. K�k
k&#305;l&#305;flar&#305; i�inde dolum defektleri g�r�lmesi tan&#305;y&#305;
kuvvetle destekler. Ayr&#305;ca radyoizotop BOS ak&#305;m
�al&#305;&#351;malar&#305; da BOS dolan&#305;m&#305;n&#305;n bozuldu&#287;u
b�lgeleri g�stermek a�&#305;s&#305;ndan yararl&#305;d&#305;r. Klinik olarak
ay&#305;r&#305;c&#305; tan&#305;da en �nemli grup MSS
infeksiyonlar&#305;d&#305;r. &#304;nfeksiyonda en �nemli ay&#305;r&#305;c&#305;
�zellik ate&#351; ve ense sertli&#287;i gibi bulgular&#305;n �n planda
olmas&#305;, fokal n�rolojik bulgular&#305;n pek g�r�lmemesidir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedavi:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Leptomeningial
metastaz tedavisinde radyoterapi ile birlikte kemoterapi uygulan&#305;r.
Radyoterapinin semptomatik b�lgelere s&#305;n&#305;rl&#305; tutulmas&#305;
toksisite a�&#305;s&#305;ndan daha olumlu olabilir. Kemoterapinin ne yolla
verilece&#287;i halen tart&#305;&#351;mal&#305; ise de, intratekal uygulama
s&#305;k�a tercih edilir. Ancak ne &#351;ekilde tedavi edilirse edilsin, solid
t�m�re ba&#287;l&#305; leptomeningial metastazl&#305; hastalarda prognoz
k�t�d�r. Hastalar tedavi edilmedi&#287;inde birka� haftal&#305;k
sa&#287;kal&#305;m s�z konusudur. Tedavi yerle&#351;mi&#351; n�rolojik
defisitleri d�zeltmese bile hastal&#305;k progresyonunu yava&#351;latabilir
veya durdurabilir; medyan sa&#287;kal&#305;m&#305;n tedavi ile birka� aya
�&#305;kmas&#305; m�mk�nd�r. Ayr&#305;ca BOS dolan&#305;m bozuklu&#287;u varsa
ventrik�loperitoneal &#351;ant tak&#305;labilir. Solid t�m�re ba&#287;l&#305;
leptomeningial metastaz&#305; olan b�t�n hastalar agresif tedavi almak zorunda
de&#287;ildir. Ya&#351;am beklentisi 3 aydan k&#305;sa olan, genel durum
bozuklu&#287;u bulunan (Karnofsky performans skalas&#305; &lt;%60) ve MSS t�m�r
y�k� �ok fazla olan hastalarda sadece destek tedavisi yapmak yeterli
olacakt&#305;r. Hematolojik neoplazilerde ise prognoz �ok daha iyidir. L�semi hastalar&#305;nda
% 75 oran&#305;nda stabilizasyon ve d�zelme g�r�l�r. Lenfomada da prognoz&nbsp;
solid t�m�rlere oranla �ok daha iyidir. Bu nedenle bu hastalar
&#305;srarl&#305; bir &#351;ekilde tedavi edilmelidir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><a name="Metastaz_d&#305;&#351;&#305;"></a><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>Metastaz
D&#305;&#351;&#305; Etkiler</span></b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�rolojik
bulgu g�steren kanserli hastalar&#305;n yar&#305;s&#305;nda n�rolojik tabloya
neden olan herhangi bir metastaz veya t�m�r yay&#305;l&#305;m&#305; saptanmaz.
Bu durumda �ok farkl&#305; nedenler n�rolojik tablodan sorumlu olabilir. Bu
nedenler a&#351;a&#287;&#305;da s&#305;ralanm&#305;&#351;t&#305;r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:13.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&#304;nfeksiy�z, Metabolik, Vask�ler Etkiler </span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;nfeksiyonlar:
</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kanserli
hastalarda hem t�m�re ba&#287;l&#305; geli&#351;en immunsupresyon, hem de
tedaviye ba&#287;l&#305; kemik ili&#287;i bask&#305;lanmas&#305; sonucu
infeksiyonlar s&#305;k g�r�l�r. Bunlar aras&#305;nda MSS infeksiyonlar&#305; da
yer al&#305;r. Bu konunun ayr&#305;nt&#305;lar&#305; <a
href="http://www.itfnoroloji.org/infeksiyon/infection.htm">Sinir Sistemi
&#304;nfeksiyonlar&#305;</a> konusunda anlat&#305;laca&#287;&#305;ndan burada
�ok k&#305;saca de&#287;inilecektir. T-lenfosit ve monon�kleer fagosit sistemi
bozuk olan hastalarda n�trofil i&#351;levleri veya total l�kosit
say&#305;s&#305; normal olsa bile; <i>Listeria </i>ve <i>Nocardia</i> gibi
bakteriyel infeksiyonlar, �zellikle kriptokok gibi mantar, herpes zoster,
herpes simpleks ve sitomegalovirus infeksiyonlar&#305; ba&#351;ta olmak �zere
virus infeksiyonlar&#305;, toksoplazmoz gibi parazitozlar ve progresif
multifokal l�koensefalopati tablosu s&#305;k g�r�l�r. Gran�lositopenisi veya
n�trofil i&#351;lev bozuklu&#287;u olan hastalarda �zellikle bakteriyel
infeksiyonlara e&#287;ilim artar. N�trofil mutlak say&#305;s&#305; 1000/mm<sup>3</sup>��n
alt&#305;nda olan hastalarda enterik basiller (<i>Ps�domonas</i> grubu, <i>E.
coli</i>, <i>Klebsiella</i>), streptokok, stafilokoklar ile birlikte <i>Listeria</i>
infeksiyonlar&#305;na ve kandida, aspergillus ve mukormikoz gibi mantar
infeksiyonlar&#305;na e&#287;ilim artar. B-lenfosit yetersizli&#287;i nadir
g�r�l�r. Bu durumda <i>S. pneumoniae</i>, <i>H. influenza</i>e ve <i>N.
meningitidis</i> infeksiyonlar&#305;na e&#287;ilim artar. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Metabolik
etkiler:</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Kanserli hastalarda pek �ok nedenle nutrisyonel ve metabolik bozukluklar
meydana gelebilir. �ncelikle kanserin tuttu&#287;u organ&#305;n
i&#351;levlerini bozmas&#305; ile o organ sistemine ait yetersizlikler
olabilir; bunlar&#305;n aras&#305;nda hipoksi, karaci&#287;er ve b�brek
yetersizliklerine ba&#287;l&#305; ensefalopatiler say&#305;labilir. Varolan
metabolik bozuklu&#287;a ba&#287;l&#305; olarak metabolik ensefalopatiler
geli&#351;ebilir. <i>Metabolik ensefalopati</i> deyimi, bozulmu&#351; serebral
metabolizma sonucu olu&#351;an davran&#305;&#351; de&#287;i&#351;ikliklerini
i�erir. Akut ya da subakut olarak geli&#351;en bu tablonun klinik
bulgular&#305;; konf�zyon, d�&#351;�nce kusurlar&#305;, davran&#305;&#351;
bozukluklar&#305;, bilin� d�zeyinde de&#287;i&#351;imler ve bazen de anormal
motor aktiviteler &#351;eklinde �zetlenebilir. �zetle; huzursuzluk, letarji,
emosyonel labilite, uyuklama ya da uykusuzluk gibi bulgulara tremor,
miyokloniler ve asteriksis gibi istemsiz hareketler e&#351;lik etti&#287;inde
bu tan&#305; olas&#305;l&#305;&#287;&#305; akla gelmelidir. Bu s&#305;k�a
kar&#351;&#305;la&#351;&#305;lan klinik tablo altta yatan nedene y�nelik tedavi
ile geriye d�ner. EEG�de yayg&#305;n yava&#351; dalga varl&#305;&#287;&#305;
saptan&#305;r. Ayr&#305;ca bu hastalarda s&#305;v&#305;-elektrolit dengesindeki
bozukluklar, �zellikle meme kanserli hastalarda hiperkalsemi s&#305;k�a
g�r�l�r. Kanserli hastalarda beslenme bozukluklar&#305; ve ka&#351;eksi de
olduk�a s&#305;kt&#305;r. Beslenme bozukluklar&#305; aras&#305;nda en s&#305;k
g�r�lenler tiamin eksikli&#287;ine ba&#287;l&#305; <i>Wernicke-Korsakoff
sendromu</i>, B12 vitamini eksikli&#287;i ve niasin eksikli&#287;ine
ba&#287;l&#305; <i>pellegra</i> say&#305;labilir. Bu sonuncusu baz&#305;
kanserlerle g�r�len ve kanserin salg&#305;lad&#305;&#287;&#305; baz&#305;
peptidlere ba&#287;l&#305; diyare ataklar&#305;na yol a�an karsinoid sendromda
s&#305;kt&#305;r. Metabolik bozukluklarla ilgili daha ayr&#305;nt&#305;l&#305;
bilgi<a href="http://www.itfnoroloji.org/metabolik/metobolik.htm"><span
style='color:windowtext;text-decoration:none;text-underline:none'> ilgili
b�l�mlerde</span></a> bulunabilir (Bak&#305;n&#305;z: <u><span
style='color:#0070C0'><a href="../metabolik/metobolik.htm">Metabolik
Ensefalopati</a></span></u> ve <u><span style='color:#0070C0'><a
href="../beslenme/beslenme.htm">Sinir sisteminin Nutrisyonel
Hastal&#305;klar&#305;</a></span></u>). </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Vask�ler
etkiler:</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Sistemik arteroskleroz oran&#305; genel pop�lasyona oranla kanserli
hastalarda daha d�&#351;�k olmas&#305;na kar&#351;&#305;n, g�r�lme
s&#305;kl&#305;&#287;&#305; a�&#305;s&#305;ndan serebrovask�ler komplikasyonlar
metastatik komplikasyondan sonra ikinci s&#305;rada yer al&#305;rlar. Kanserli
hastalarda kanay&#305;c&#305; ve t&#305;kay&#305;c&#305; serebrovask�ler
olaylar yakla&#351;&#305;k e&#351;it oranlarda g�r�l�r. Kanay&#305;c&#305;
olaylar intraserebral kanamalar, kranyal ve spinal subdural ve epidural
kanamalar ve nadiren subaraknoid kanama &#351;eklinde kar&#351;&#305;m&#305;za
�&#305;kabilir. Kanay&#305;c&#305; olaylar&#305;n alt&#305;nda
s&#305;kl&#305;kla koag�lasyon bozukluklar&#305; bulunur. Kemik ili&#287;inin
t�m�r infiltrasyonuna veya ila�larla bask&#305;lanmas&#305;na ba&#287;l&#305;
trombositopeni, trombosit i&#351;lev bozukluklar&#305;, karaci&#287;er
yetersizli&#287;ine ba&#287;l&#305; K vitamini eksiklikleri kanserli hastalarda
s&#305;k g�r�len kanama nedenleridir. Trombositopenili hastalarda lomber
ponksiyon yap&#305;lmas&#305; gerekiyorsa �ncesinde trombosit suspansiyonu
verilerek kanda trombosit say&#305;s&#305;n&#305;n 20 000/ mm<sup>3</sup>
d�zeyinin �zerine �&#305;kar&#305;lmas&#305; gerekir, ayr&#305;ca ince
i&#287;ne ile (no. 20 veya 22) ve �ok dikkatli bir &#351;ekilde ponksiyon
yap&#305;lmal&#305;d&#305;r. Aksi halde spinal subdural veya epidural kanama
geli&#351;ebilir. Bazen t�m�r�n t�m�r veya metastazlar&#305;n&#305;n i�ine kanama
da g�r�lebilir. En s&#305;k kanayan beyin metastazlar&#305; melanom,
koryokarsinom, akci&#287;er, renal ve s�rrenal kanserlerine aittir. Kanserli
hastalarda g�r�lebilen iskemik serebrovask�ler olaylar&#305;n
yakla&#351;&#305;k ��te birinin alt&#305;nda klasik aterosklerotik damar
darl&#305;klar&#305; bulunur. Geri kalan �o&#287;unlu&#287;unda farkl&#305; nedenler
s�z konusudur. Bunlar aras&#305;nda disemine intravask�ler koag�lasyon (DIC),
non-bakteriyel trombotik endokardit, septik emboli, t�m�r embolisi, t�m�r
bas&#305;s&#305; ile arter t&#305;kanmas&#305;n&#305;n yan&#305; s&#305;ra
meme, mide, akci&#287;er kanserleri ve lenfomada g�r�lebilen trombotik
mikroanjiyopati ile intravask�ler lenfoma say&#305;labilir. Kanserli hastalarda
yayg&#305;n (disemine) intravask�ler koag�lasyon t&#305;kay&#305;c&#305;,
trombotik vask�ler hastal&#305;klar i�erisinde ilk s&#305;ray&#305; al&#305;r.
Her t�rl� malinitede g�r�lmekle birlikte l�koz ve lenfomalarda daha
s&#305;kt&#305;r. Genelde �l�mle sonlanan bu klinik tablo; akut geli&#351;en
ensefalopati, buna eklenen fokal ya da jeneralize konv�lsiyonlar ile
karakterizedir. Fokal n�rolojik bulgu varsa hafiftir. Serebral ven�z
okl�zyonlar ise her t�rl� sistemik kanserde g�r�lmekle birlikte l�koz ve
lenfomalarda s&#305;kt&#305;r. &#350;iddetli ba&#351;
a&#287;r&#305;s&#305;n&#305; izleyen konv�lsiyonlarda bu tan&#305; akla
gelmelidir. Yine baz&#305; kanserlerin (jinekolojik, meme, akci&#287;er
kanserleri ve hematolojik neoplaziler) salg&#305;lad&#305;&#287;&#305;
pro-koagulan maddeler ile baz&#305; kanserlerde de (prostat, meme) dural
metastazlar nedeni ile maj�r ven�z sin�slerde t&#305;kanma g�r�lebilir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:13.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Tedavi Komplikasyonlar&#305;</span></b><span lang=TR style='font-size:13.0pt;
font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kemoterapi
Yan Etkileri </span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kanser
tedavisinde kullan&#305;lan kemoterap�tiklere ba&#287;l&#305; g�r�lebilen
n�rolojik yan etkiler <b>Tablo 5</b>�te s&#305;ralanm&#305;&#351;t&#305;r.
S&#305;k g�r�len baz&#305; �zel durumlar burada biraz daha
ayr&#305;nt&#305;l&#305; olarak ele al&#305;nacakt&#305;r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>Tablo 5. N�rotoksik etki g�steren kemoterap�tikler </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(Kaynak
3 ve 26�dan)) </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:#FFFFCC;mso-padding-alt:
 0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>Akut ensefalopati (delirium)</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=DE
  style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'>Metotreksat (intraven�z veya intratekal),
  kortikosteroidler, sis-platin, vinkristin, asparaginaz, prokarbazin,
  5-florourasil, Ara-C, nitroz�reler, siklosporin, interl�kin-2, ifosfamid/
  mesna, interferonlar, tamoksifen, VP-16, PALA, bevasizumab, kapesitabine,
  etoposid, paklitaksel</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:TR'>Kronik
  ensefalopati (demansiyel sendrom)</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> <br>
  Metotreksat , BCNU, Ara-C, fludarabin</span><span lang=DE style='mso-ansi-language:
  DE'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>G�rme kayb&#305;</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> </span><span lang=DE style='mso-ansi-language:
  DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'>Tamoksifen, galyum nitrat,
  nitroz�reler, sis-platin </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:TR'>Serebellar
  bozukluk/ ataksi</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'> <br>
  5-florourasil, Ara-C, prokarbazin, vinkristin, siklosporin A </span><span
  lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:TR'>Aseptik
  menenjit</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'> <br>
  monoklonal antikorlar, OKT 3, Ara-C (intratekal), metotreksat (intratekal) </span><span
  lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;a&#287;r&#305;s&#305;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  Tamoksifen, temozolamid</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:TR'>Epileptik
  n�bet</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  Metotreksat, etoposid, sis-platin, vinkristin, asparaginaz, nitrojen mustard,
  prokarbazin, BCNU, dakarbazin, busulfan, siklosporin, ifosfamid, paklitaksel,
  klorambusil</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:TR'>Miyelopati
  (intratekal ajanlar)</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  Metotreksat, Ara-C, tiotepa </span><span lang=DE style='mso-ansi-language:
  DE'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>Periferik n�ropati</span><span lang=DE
  style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Vinka alkaloidleri, sis-platin, prokarbazin, 5-azasitidin, etoposid,
  5-florourasil, Ara-C, taksol, suramin, mitotan, bortezomab, dosetaksel,
  oksaliplatin, teniposid, talidomid</span><span lang=DE style='mso-ansi-language:
  DE'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Periferik
n�ropati:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Kemoterapiye ba&#287;l&#305; periferik n�ropati genellikle distal-simetrik
bir polin�ropatidir. Nadiren fokal n�ropatiler g�r�lebilir. Suramin demiyelinizan,
duysal-motor n�ropatiye yol a�arken, vinkristin aksonal duysal-motor n�ropatiye
yol a�ar. Her ikisi de tedavinin kesilmesi ile bir miktar d�zelebilir. Taksol
ve sis-platin ise saf duysal n�ropatiye yol a�ar. Sis-platin ile sadece
kal&#305;n lifler tutulurken, taksol ile ince lifler de tutulur. Arka k�k
gangliyonundaki hasar&#305;n d�zeyine ba&#287;l&#305; de&#287;i&#351;mekle
birlikte tedavinin kesilmesi ile d�zelebilir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Metotreksat
toksisitesi:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Bir folik asit antagonisti olan metotreksat ile ili&#351;kili akut veya
kronik n�rotoksisite olduk�a iyi bilinir. En s&#305;k g�r�len metotreksat
toksisitesi <i>aseptik menenjit</i>tir. &#304;ntratekal metotreksat alan
hastalar&#305;n % 10�unda g�r�l�r. Genellikle ilac&#305;n verilmesinden 2-4
saat sonra ba&#351;lar, 12-72 saat s�rer. Daha nadir bir komplikasyon ilac&#305;n
intraventrik�ler uygulanmas&#305;ndan sonra g�r�lebilen <i>akut ensefalopati</i>dir.
Bu durum bazen, �zellikle kranyal &#305;&#351;&#305;nlama sonras&#305;nda
y�ksek doz intraven�z metotreksat uygulamas&#305; ile de g�r�lebilir.
Genellikle 24-48 saat i�inde ba&#351;layan ve kendili&#287;inden d�zelen
konf�zyon, uykuya e&#287;ilim ve n�betlerle kendini g�sterir. Yine y�ksek doz
intraven�z metotreksat sonras&#305;nda 5.-6. g�nde g�r�len ve inme-benzeri
tablolarla kendini g�steren <i>subakut bir ensefalopati </i>g�r�lebilir. Bu
durum da 1-2 g�n i�inde kendili&#287;inden d�zelir. �ok nadir olarak intratekal
metotreksat tedavisinin bir komplikasyonu olarak <i>transvers miyelit</i>
g�r�l�r. Genellikle intratekal injeksiyondan sonra ilk 48 saat i�inde, nadiren
ilk 2 hafta i�inde ortaya �&#305;kar. D�zelme de&#287;i&#351;kendir. Baz&#305;
olgular tam d�zelirken, baz&#305;ar&#305;nda hi� d�zelme g�r�lmeyebilir.
Metotreksat tedavisinin en ciddi yan etkilerinden biri <i>kronik
l�koensefalopati</i>dir. Genellikle yineleyen y�ksek doz intraven�z veya
intratekal metotreksat tedavisinden aylar veya y&#305;llar sonra geli&#351;ir.
Ani ba&#351;layan veya yava&#351; geli&#351;en mental gerileme ve
davran&#305;&#351; de&#287;i&#351;iklikleri ortaya �&#305;kar. Seyir
de&#287;i&#351;kendir; bazen &#305;l&#305;ml&#305; bir demansiyel tablo olarak
stabilize olurken, baz&#305; durumlarda ilerleyici bir gidi&#351;le spastik
tetraparezi, n�betler ve �l�mle sonlanabilir. Yayg&#305;n miyelin
y&#305;k&#305;m&#305;na ba&#287;l&#305; olarak MR�da yayg&#305;n ak madde
hiperintensitesi g�r�n�r. Metotreksatla birlikte kranyal radyoterapi
uygulanm&#305;&#351; hastalarda l�koensefalopati g�r�lme &#351;ans&#305; ve
&#351;iddeti daha fazlad&#305;r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Radyoterapi
Yan Etkileri:</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Radyoterapi uygulanan
MSS b�lgesi ortaya �&#305;kacak yan etkiler a�&#305;s&#305;ndan da
belirleyicidir. Sinir sistemine radyasyon toksisitesi zamansal olarak
genellikle �� ana ba&#351;l&#305;k alt&#305;nda incelenebilir: 1. akut, 2.
erken-gecikmi&#351;, 3. ge�-gecikmi&#351; radyasyon toksisitesi. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>A. Radyasyon
Ensefalopatisi:</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>1. <i>Akut
ensefalopati:</i> Kafa i�i bas&#305;n� art&#305;&#351;&#305;na yol
a�m&#305;&#351; b�y�k t�m�rlerde b�y�k bir fraksiyon halinde (&gt;300 cGy)
radyoterapi uygulanmas&#305;ndan sonra ortaya �&#305;kar. �ncesinde steroid
verilmemesi riski artt&#305;r&#305;r. Tedaviden hemen sonra veya birka� saat
i�inde n�rolojik tabloda k�t�le&#351;me, ba&#351;a&#287;r&#305;s&#305;,
bulant&#305;-kusma, uyan&#305;kl&#305;k kusuru ve ate&#351; geli&#351;ir;
genellikle kendine s&#305;n&#305;rl&#305; bir tablo olsa da nadiren �l�mc�l
olabilir. Bu durumun �nlenmesi i�in radyoterapi fraksiyonlar&#305;n&#305;n 200
cGy�in alt&#305;nda tutulmas&#305; ve 24-72 saat �ncesinden 16 mg/g�n
deksametazon ba&#351;lanmas&#305; �nerilmektedir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>2. <i>Erken
gecikmi&#351; ensefalopati: </i>Gerek beyin t�m�r� nedeniyle gerekse
profilaktik olarak kranyal radyoterapi alan hastalarda radyoterapiden sonraki 2
hafta- 4 ay i�inde ortaya �&#305;kar. Hastada ba&#351;a&#287;r&#305;s&#305;,
uykuya e&#287;ilim ba&#351;lar, eski n�rolojik bulgular tekrar belirir ve
k�t�le&#351;ir. Bu durumu klinik ve radyolojik olarak primer t�m�r�n n�ks�nden
ay&#305;rdetmek �ok zordur. BT ve MRG�de kontrast tutan, etraf&#305; �demli bir
b�lge g�r�l�r. PET incelemesi ayr&#305;m&#305; sa&#287;layabilir. Bu tablonun
t�m�r n�ks�nden tek fark&#305;, hem klinik hem de radyolojik tablonun birka�
hafta i�inde kendili&#287;inden d�zelme g�stermesidir. Steroidler bu d�zelmeyi
h&#305;zland&#305;rabilir. Bu nedenle b�yle hastalar steroid tedavisi
alt&#305;nda s&#305;k g�r�nt�lemelerle izlenmelidir. Yap&#305;lm&#305;&#351;
histopatolojik incelemeler akson kayb&#305;n&#305;n geri planda oldu&#287;u
demiyelinizasyonu g�sterir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>3. <i>Ge�
gecikmi&#351; ensefalopati:</i> Radyasyon nekrozu genellikle beyin t�m�r� veya
ba&#351;-boyun t�m�rleri nedeniyle yap&#305;lan kranyal radyoterapi
tamamland&#305;ktan sonraki 1-2 y&#305;l i�inde ortaya �&#305;kar. BT ve MRG�de
beyin t�m�rl�lerde eski t�m�r b�lgesinde, ba&#351;-boyun t�m�rl�lerde de
&#305;&#351;&#305;nlanan alandaki beyin parenkiminde kontrast tutulumu ile
�evresel �dem g�r�l�r. Bu durumun da klinik ve radyolojik olarak primer t�m�r�n
n�ks�nden ay&#305;rdedilmesi �ok zordur. Yukar&#305;da s�zedildi&#287;i gibi,
PET incelemesi veya MR spektroskopi ayr&#305;m&#305; sa&#287;layabilir.
Histolojik olarak radyasyon nekrozunun yukar&#305;da s�z� ge�en kronik metotreksat
ensefalopatisinden ay&#305;rdedilmesi de g��t�r. Kranyal radyoterapi
sonras&#305;nda radyonekroz s&#305;kl&#305;&#287;&#305; % 3-5
aras&#305;ndad&#305;r. Olgular&#305;n �ok daha b�y�k bir k&#305;sm&#305;nda ise
sadece kortikal ve subkortikal atrofi g�r�l�r. Radyoterapi ile birlikte metotreksat
da verilmi&#351;se l�koensefalopati geli&#351;me riski artar. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>B.
Radyasyon Miyelopatisi: </span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>(Ayr&#305;ca bak&#305;n&#305;z: <u><span
style='color:#0070C0'><a href="../omurilik/omurilik.htm">Omurilik
Hastal&#305;klar&#305;</a></span></u>) </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>1. <i>Akut
miyelopati</i>: Spinal radyoterapi sonras&#305;nda akut miyelopati g�r�l�p
g�r�lmeyece&#287;i tart&#305;&#351;mal&#305; bir konudur. Tedavinin ilk
g�nlerinde ortaya �&#305;kabilece&#287;i gibi haftalar i�erisinde de
olu&#351;abilir. Genelde, boyun b�lgesinin
&#305;&#351;&#305;nlanmas&#305;n&#305; izleyerek ortaya �&#305;kan <i>Lhermitte
belirtisi</i> ile tan&#305;n&#305;r. Medulla spinalisdeki fokal demiyelizasyona
ba&#287;l&#305; olarak hasta ba&#351;&#305;n&#305; fleksiyona getirdi&#287;inde
g�vde ve bacaklara, bazen de kollara yay&#305;lan, anl&#305;k bir elektriklenme
hissinden yak&#305;n&#305;r. Haftalar i�erisinde spontan olarak d�zelen bu
tablo i�in tedavi gerekli de&#287;ildir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>2. <i>Erken
gecikmi&#351; miyelopati</i>: Radyoterapiden sonraki 3-5 ay i�inde ortaya
�&#305;kan paresteziler ve <i>Lhermitte</i> bulgusu ile karakterizedir. Bu
tablodan arka kordonlarda ortaya �&#305;kan demiyelinizasyonun sorumlu
oldu&#287;u d�&#351;�n�lmektedir. Genellikle de birka� ay i�inde
kendili&#287;inden d�zelir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>3. <i>Ge�
gecikmi&#351; miyelopati</i>: Ge� radyasyon miyelopatisi ba&#351;l&#305;ca �� &#351;ekilde
g�r�l�r. En s&#305;k g�r�leni 1-4 y&#305;l i�inde ba&#351;lay&#305;p
h&#305;zl&#305; veya yava&#351; bir progresyonla paraparezi veya tetraparezi
ile sonlan&#305;r. Klinik tablo; a&#287;r&#305;s&#305;z ve �ncelikle medulla
spinalisin daha �ok radyasyon alan yar&#305;s&#305; etkilenmi&#351;
oldu&#287;undan tam ya da parsiyel bir <i>Brown-Sequard sendromu</i> olarak
kar&#351;&#305;m&#305;za �&#305;kar. Benzer bir klinik tabloya yol a�abilecek
epidural bas&#305; gibi olas&#305;l&#305;klar&#305;n d&#305;&#351;lanmas&#305;
i�in MRG yap&#305;lmal&#305;d&#305;r. MRG bas&#305;y&#305; d&#305;&#351;lar;
genellikle normaldir, ancak omurilikte kontrast tutan hafif &#351;i&#351; bir
b�lge g�r�lebilir. Radyoterapi b�lgesi hakk&#305;nda ayr&#305;nt&#305;l&#305;
bilgi yoksa, &#305;&#351;&#305;nlanan b�lgedeki vertebra
korpuslar&#305;n&#305;n ya&#287;l&#305; doku nedeniyle hiperintens g�r�nmesi
&#305;&#351;&#305;nlanan b�lgenin s&#305;n&#305;rlar&#305; hakk&#305;nda ipucu
verir. Omurilik parenkim hasar&#305; d&#305;&#351;&#305;nda pelvik
&#305;&#351;&#305;nlamay&#305; izleyerek alt ekstremitelerde ortaya �&#305;kan
motor n�ron sendromu ve intraspinal kanamalar da spinal radyoterapinin ge�
komplikasyonlar&#305; olarak kar&#351;&#305;m&#305;za �&#305;kabilir. Bu iki
durum da radyoterapiden uzun y&#305;llar sonra g�r�lebilir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>C.
Radyasyona Ba&#287;l&#305; Kranyal ve Periferik N�ropatiler</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Radyasyona
ba&#287;l&#305; kranyal ve periferik n�ropatiler nadiren de olsa g�r�lebilir.
Optik n�ropati radyoterapiden 6 ay-2 y&#305;l sonra geli&#351;en
a&#287;r&#305;s&#305;z tek veya iki yanl&#305; k�rl�k ile ortaya �&#305;kar.
Papil�dem g�r�lebilir. MRG�de optik sinirde kontrast tutulumu olabilir. Benzer
&#351;ekilde di&#287;er kranyal sinirlerde de radyasyon hasar&#305; nadiren
bildirilmi&#351;tir. Bunlar&#305;n d&#305;&#351;&#305;nda radyasyon
pleksopatileri g�r�lebilir. Genellikle radyoterapiden bir y&#305;l&#305;
a&#351;k&#305;n s�re sonra ge�-gecikmi&#351; tablolar ortaya �&#305;kar.
A&#287;r&#305;s&#305;z zaaf ve duyu kusuru olur. Radyasyon pleksopatisini
olas&#305; bir t�m�r infiltrasyonundan ay&#305;rmak �nemlidir. T�m�r
infiltrasyonu genellikle a&#287;r&#305;l&#305;d&#305;r. Ayr&#305;ca, i&#287;ne
EMG�sinde tutulan kaslarda miyokimi varl&#305;&#287;&#305; radyasyon
pleksopatisi i�in olduk�a tan&#305; koydurucu say&#305;l&#305;r
(Bak&#305;n&#305;z: <u><span style='color:#0070C0'><a
href="../spinalsinir/spinalsinir.html">Spinal Sinirlerin Hastal&#305;klar&#305;</a></span></u>).
</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>D.
Radyasyonun &#304;ndirekt Etkileri</span></i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Burada s�z�
edilmesi gereken ba&#351;l&#305;ca konular kranyal &#305;&#351;&#305;nlamadan
y&#305;llar sonra ortaya �&#305;kan <i>ikincil t�m�rler</i>, <i>b�y�k damar
hastal&#305;&#287;&#305;</i> ve <i>hipotalamo-hipofizer yetmezlik</i>
tablolar&#305;d&#305;r. �ocukluk �a&#287;&#305;nda kranyal
&#305;&#351;&#305;nlama yap&#305;lm&#305;&#351; hastalarda ileride meningiom,
gliom, Schwannom gibi t�m�rlerin geli&#351;me riski anlaml&#305; olarak daha
y�ksektir. Ortalama latans ise yakla&#351;&#305;k 17 y&#305;ld&#305;r. Benzer
&#351;ekilde radyoterapiden y&#305;llar sonra damarsal komplikasyonlar
geli&#351;ebilir. Radyoterapi her boyda damar �zerinde olumsuz etki g�sterir.
K���k damarlarda t&#305;kanma yukar&#305;da s�z edilen radyonekroza yol a�ar.
Bunun d&#305;&#351;&#305;nda &#305;&#351;&#305;nlama penceresi i�inde kalan
b�y�k serebral damarlarda da h&#305;zlanm&#305;&#351; ateroskleroz g�r�l�r;
ancak ortaya �&#305;kan darl&#305;klar&#305;n yerle&#351;imi atipiktir. Bu
durum radyoterapiden aylar veya y&#305;llar sonra belirti verebilir. Burada
yakla&#351;&#305;m klasik aterosklerotik hastal&#305;ktan farks&#305;zd&#305;r.
</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Sinir Sisteminin Paraneoplastik Sendromlar&#305;</span></b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span><span
lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Genel
�zellikler</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>T�m�rlerin
metastaz, direkt yay&#305;l&#305;m, metabolik ve vask�ler etkilerinin
d&#305;&#351;&#305;nda sinir sistemi �zerindeki uzak etkileri paraneoplastik
sendromlar olarak tan&#305;mlan&#305;r. N�rolojinin olduk�a nadir
kar&#351;&#305;la&#351;&#305;lan hastal&#305;klar&#305; olmalar&#305;na
kar&#351;&#305;n, sistemik bir kanserin erken habercisi olmalar&#305; nedeniyle
�nem ta&#351;&#305;rlar. Paraneoplastik sendromlar&#305;n en belirgin
�zelli&#287;i, genellikle t�m�r tan&#305;s&#305;ndan �nce belirti vermesidir.
Bu nedenle hasta �o&#287;u zaman �nce n�roloji ile u&#287;ra&#351;an hekimin
kar&#351;&#305;s&#305;na gelir ve tan&#305;y&#305; burada almas&#305; gerekir.
&#304;kincisi, paraneoplastik sendromlar&#305;n alt&#305;nda yatan t�m�rlerin
genellikle benzerlerine oranla daha s&#305;n&#305;rl&#305; ve sinsi seyirli
olmas&#305;, bu nedenle tedavi edilebilir olmas&#305;d&#305;r. Paraneoplastik
sendrom belirtileri ortaya �&#305;kt&#305;&#287;&#305;nda t�m�r genellikle
b�lgesel lenf nodlar&#305; d&#305;&#351;&#305;nda non-metastatiktir. Buna
kar&#351;&#305;n n�rolojik tablo s&#305;kl&#305;kla a&#287;&#305;rd&#305;r ve
ciddi �z�rl�l�k yarat&#305;r; �o&#287;u zaman da geri d�n�&#351;s�zd�r.
N�rolojik tablo genellikle subakut ba&#351;lar, haftalar-aylar i�inde ilerler,
belirli bir d�zeye ula&#351;&#305;nca da orada stabilize olur. Bu nedenle
n�rolojik tablonun erken tan&#305;nmas&#305; da, t�m�r�n ilerlemeden tedavi
edilme &#351;ans&#305;n&#305; verir. Bu tablolar&#305;n bir di&#287;er �nemli
�zelli&#287;i de, a&#351;a&#287;&#305;da daha ayr&#305;nt&#305;l&#305;
anlat&#305;laca&#287;&#305; gibi, paraneoplastik sendrom tipinin aranacak
kanserin tipi hakk&#305;nda ipucu vermesi ve b�ylece kanserin
aranaca&#287;&#305; b�lgeye hekimi y�neltmesidir (<b>Tablo 6</b>). Orta
ya&#351;&#305;n �zerindeki hastalarda, subakut olarak geli&#351;en duysal
polin�ropati, serebellar sendrom, dermatomiyozit ve Lambert-Eaton sendromu
tan&#305;lar&#305;n&#305;n alt&#305;nda mutlak sistemik bir malignitenin
varl&#305;&#287;&#305; ara&#351;t&#305;r&#305;lmal&#305;d&#305;r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>Tablo 6. Sinir sisteminin paraneoplastik sendromlar&#305;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width=614 style='width:460.5pt;
 mso-cellspacing:1.5pt;background:#FFFFCC;border:outset gray 1.0pt;mso-padding-alt:
 0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width="50%" valign=top style='width:50.0%;border:inset gray 1.0pt;
  background:#FF6666;padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>Merkezi sinir sistemi</span></p>
  </td>
  <td width="50%" valign=top style='width:50.0%;border:inset gray 1.0pt;
  background:#FF6666;padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>Periferik sinir / kas</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes'>
  <td width="50%" valign=top style='width:50.0%;border:inset gray 1.0pt;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>�Klasik� paraneoplastik sendromlar</span></b><span lang=DE
  style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l5 level1 lfo16;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Subakut
       serebellar dejenerasyon </span><span lang=DE style='mso-ansi-language:
       DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l5 level1 lfo16;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       ensefalomiyelit (PEM) (<u>+</u>SSN) </span><span lang=DE
       style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l5 level1 lfo16;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Opsoklonus-miyoklonus-ataksi
       </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l5 level1 lfo16;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�Stiff-person�
       sendromu </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l5 level1 lfo16;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Limbik ensefalit
       </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
  </ul>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Klasik olmayan paraneoplastik sendromlar</span></b><span lang=DE
  style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l12 level1 lfo19;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       beyinsap&#305; ensefaliti </span><span lang=DE style='mso-ansi-language:
       DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l12 level1 lfo19;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nekrotizan
       miyelopati </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l12 level1 lfo19;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       motor n�ron hastal&#305;&#287;&#305; </span><span lang=DE
       style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l12 level1 lfo19;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       retinopati/ optik n�ropati </span></li>
  </ul>
  </td>
  <td width="50%" valign=top style='width:50.0%;border:inset gray 1.0pt;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>�Klasik� paraneoplastik sendromlar</span></b></p>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l9 level1 lfo22;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Subakut duysal
       n�ronopati (SSN) (<u>+</u>PEM)&nbsp; </span><span lang=FR
       style='mso-ansi-language:FR'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l9 level1 lfo22;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Subakut
       sensori-motor n�ropati </span></li>
   <li class=MsoNormal style='mso-list:l9 level1 lfo22;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Lambert-Eaton
       miyastenik sendromu </span></li>
   <li class=MsoNormal style='mso-list:l9 level1 lfo22;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�romiyotoni </span></li>
   <li class=MsoNormal style='mso-list:l9 level1 lfo22;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Dermatomiyozit </span><span
       lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
  </ul>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></b><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></b><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Klasik olmayan paraneoplastik sendromlar</span></b><span lang=DE
  style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l11 level1 lfo25;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Polimiyozit </span><span
       lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l11 level1 lfo25;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>AIDP / CIDP </span><span
       lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l11 level1 lfo25;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Vask�litik
       n�ropati </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l11 level1 lfo25;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Miyastenia
       gravis </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l11 level1 lfo25;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nekrotizan
       miyopati </span></li>
  </ul>
  </td>
 </tr>
</table>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
sendromlar kad&#305;nlarda erkeklere oranla daha s&#305;k g�r�l�r. Tam olarak insidensi
bilinmemekle beraber, klinik olarak belirti veren paraneoplastik sendrom,
kanserli hastalar&#305;n % 5�inden az&#305;nda g�r�l�r. S&#305;k
kar&#351;&#305;la&#351;&#305;lan maligniteler k���k h�creli akci&#287;er
kanseri (olgular&#305;n %3��nde paraneoplastik sendrom geli&#351;ir), timoma
(olgular&#305;n %15�inde paraneoplastik sendrom geli&#351;ir) ve monoklonal
gamopatiler ile ili&#351;kili hematolojik malignitelerdir (olgular&#305;n
%5-15�inde paraneoplastik sendrom geli&#351;ir). K���k h�creli akci&#287;er
kanseri d&#305;&#351;&#305; solid t�m�rlerde paraneoplastik sendrom g�r�lme
s&#305;kl&#305;&#287;&#305; %1�in alt&#305;ndad&#305;r. Subklinik
olgular&#305;n % 50�lere ula&#351;abilece&#287;ini �ne s�ren yazarlar varsa da
bu konu netlik kazanmam&#305;&#351;t&#305;r. Paraneoplastik sendrom
semptomlar&#305;, olgular&#305;n %60�&#305;nda kanser tan&#305;s&#305;ndan �nce
ortaya �&#305;karken, %40�&#305;nda t�m�r tan&#305;s&#305;ndan sonra veya n�ks
s&#305;ras&#305;nda ortaya �&#305;kar. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
sendromlar&#305;n tan&#305;s&#305; n�rolojik sendromun tan&#305;nmas&#305;,
ili&#351;kili kanserin g�sterilmesi ve serum/BOS antikorlar&#305;n&#305;n
saptanmas&#305; ile konur. Merkezi sinir sistemini ilgilendiren paraneoplastik
sendromlarda n�roradyolojik incelemeler, baz&#305; istisnalar
d&#305;&#351;&#305;nda s&#305;kl&#305;kla negatif kal&#305;r; �o&#287;u zaman
parenkim atrofisi d&#305;&#351;&#305;nda bulgu vermez. Lezyon saptanabilen
olgularda ise kan-beyin bariyeri korunmu&#351; oldu&#287;undan genellikle
kontrast tutan lezyon bulma olas&#305;l&#305;&#287;&#305; d�&#351;�kt�r. Ancak
baz&#305; istisnalar da vard&#305;r. Paraneoplastik limbik ensefalit
olgular&#305;nda limbik sistem yap&#305;lar&#305; MR�da hiperintens
g�r�nebilir. MR incelemesinin negatif oldu&#287;u paraneoplastik ensefalit
olgular&#305;nda FDG-PET incelemesinin merkezi sinir sistemi
lezyonlar&#305;n&#305; g�sterebildi&#287;i bildirilmi&#351;tir. Ensefalit
olgular&#305;nda g�r�lebilen non-konv�lzif epileptik status tablosu EEG
incelemesi ile saptanabilir. Periferik sinir sistemini ve kas&#305;
ilgilendiren paraneoplastik sendromlarda EMG tan&#305;ya yard&#305;mc&#305;d&#305;r.
BOS normal olabilirse de s&#305;kl&#305;kla inflamatuvar �zellikler g�sterir.
Il&#305;ml&#305; veya orta d�zeyde pleositoz, protein art&#305;&#351;&#305;,
&#304;gG art&#305;&#351;&#305; ve oligoklonal bantlar g�r�lebilir.
Paraneoplastik sendroma benzer tablolar&#305;n kanser d&#305;&#351;&#305; pek
�ok sebeple de ortaya �&#305;kabildi&#287;i unutulmamal&#305;d&#305;r. Kanser
metastaz&#305;, f&#305;rsat�&#305; infeksiyonlar ve kemoterapi/radyoterapi yan
etkileri bunlardan baz&#305;lar&#305;d&#305;r. Karsinomat�z menenjiti
d&#305;&#351;lamak i�in de lomber ponksiyon yap&#305;lmas&#305; gereklidir.
Kanseri bulunmayan baz&#305; hastalarda benzer tablolar&#305;n otoimmun
hastal&#305;klar&#305;n seyri s&#305;ras&#305;nda da g�r�lebilece&#287;i
unutulmamal&#305;d&#305;r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
sendromlar genelikle kanserin erken evrelerinde geli&#351;ir ve bu y�zden
t�m�r�n g�sterilmesi m�mk�n olmayabilir. Altta yatan t�m�r, �o&#287;u zaman,
g�&#287;�s, abdomen ve pelvis BT�si ile g�sterilebilir. Sendromun veya
paraneoplastik antikorun bilinmesi, g�r�nt�lenmesi hedeflenen b�lgenin daha iyi
se�ilmesini sa&#287;lar (anti-Yo pozitif olguda mamografi, anti-Ma pozitif
olguda testis ultrasonografisi gibi). FDG-PET incelemesi k���k primer
t�m�rlerin ve metastazlar&#305;n g�sterilmesini ve biyopsi i�in olas&#305;
b�lgelerin belirlenmesini sa&#287;lar.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Patogenez</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
sendromlar&#305;n neden ve nas&#305;l ortaya �&#305;kt&#305;klar&#305; tam
olarak bilinmemekle beraber, ge�mi&#351; y&#305;llardan bu yana patogenezde
baz&#305; teoriler ileri s�r�lmektedir. Bug�n en yayg&#305;n kabul g�ren teori
otoimm�n teoridir. Otoimm�n hastal&#305;&#287;a, ya f&#305;rsat�&#305;
infeksiyona ba&#287;l&#305; molek�ler taklit, ya da t�m�rde baz&#305;
onko-n�ral antijenlerin ekspresyonunun yol a�t&#305;&#287;&#305;
d�&#351;�n�lmektedir. Ancak, paraneoplastik sendromun s&#305;kl&#305;kla erken
d�nemde kanser hen�z s&#305;n&#305;rl&#305; iken geli&#351;ti&#287;i, yani
t�m�re ba&#287;l&#305; immunsupresyonun geli&#351;mesinden �nce ortaya
�&#305;kt&#305;&#287;&#305; d�&#351;�n�l�rse, f&#305;rsat�&#305; enfeksiyonlar&#305;n
pek s�z konusu olamayaca&#287;&#305; g�r�lmektedir. Bu durumda ikinci
olas&#305;l&#305;k daha akla yak&#305;n g�r�nmektedir. Onko-n�ral antijenler
fetal ya&#351;am sonras&#305; periferik dokularda kaybolan ve MSS i�ine
sekestre olan antijenlerdir. MSS�nin ba&#287;&#305;&#351;&#305;kl&#305;k
sisteminden korunmu&#351; yap&#305;s&#305; i�inde yer alan bu ilkel antijenler,
baz&#305; t�m�rler taraf&#305;ndan da sergilenir ve t�m�re y�nelen
ba&#287;&#305;&#351;&#305;kl&#305;k sistemi �gelerinin hedefi haline gelir. Bu
antijenlerin �ncelikle CD4-haf&#305;za T-lenfositlerini aktive etti&#287;i
d�&#351;�n�lmektedir. Ayn&#305; zamanda, B-lenfositler aktive olur ve otoantikor
�retimi ba&#351;lar. Bu otoantikorlar&#305;n patogenezdeki ger�ek rol� tam
olarak bilinmemektedir. MSS hasar&#305;n&#305;n sitotoksik T-lenfosit
yan&#305;t&#305; sonucunda ger�ekle&#351;ti&#287;i d�&#351;�n�lmektedir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Paraneoplastik Sendromlarda Otoantikorlar (Tablo 7 ve 8):</span></i></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Paraneoplastik oldu&#287;u bilinen pek �ok hastal&#305;kta &#304;gG
yap&#305;s&#305;nda otoantikorlar saptanmaktad&#305;r. Bu otoantikorlar
tan&#305;d&#305;klar&#305; antijene g�re isimlendirilse de (anti-amfifizin
gibi), ilk tan&#305;mlanan otoantikorlar s&#305;ras&#305;nda kullan&#305;lan
bir y�ntemle antikorun ilk kez g�sterildi&#287;i hastan&#305;n ad&#305;n&#305;n
ilk iki harfi ile de adland&#305;r&#305;l&#305;rlar (ani-Hu, anti-Yo, anti-Ri,
gibi). Baz&#305; t�m�rlere ve baz&#305; paraneoplastik sendromlara �zg�
otoantikorlar vard&#305;r. Her otoantikor sinir sisteminin belirli h�crelerinin
belirli b�l�mleri ile ve bir de t�m�rle immunhistokimyasal reaksiyon verir;
genellikle hastan&#305;n ba&#351;ka dokular&#305;yla veya ba&#351;ka
hastalardan elde edilen benzer tipteki t�m�r dokusu ile reaksiyon vermez.
Hastalar&#305;n serum veya BOS �rneklerinde anti-n�ronal antikorlar&#305;n
g�sterilmesi tan&#305;y&#305; kolayla&#351;t&#305;rmakla beraber olgular&#305;n
%40�&#305;nda antikor g�sterilemez. Bu antikorlar sa&#287;l&#305;kl&#305;
ki&#351;ilerde bulunmaz, paraneoplastik sendrom yaratmayan benzer kanserlerde
ya bulunmaz, ya da �ok d�&#351;�k titrededirler. Genellikle BOS�taki antikor
d�zeyi serumdakinden �ok daha y�ksektir; bu intratekal antikor sentezinin de
bulundu&#287;unu g�sterir. Bu antikorlar&#305;n paraneoplastik hastal&#305;k
olu&#351;umunda oynad&#305;klar&#305; rol tam bilinmemektedir. Hedef
antijenlerin h�cre y�zeyindeki resept�rler oldu&#287;u Lambert-Eaton miyastenik
sendromu ve miyastenia gravis gibi �ok az say&#305;da tabloda ve ayr&#305;ca
anti-amfifizinle ili&#351;kili �stiff-person� sendromunda paraneoplastik
antikorlar&#305;n hastal&#305;&#287;a yol a�t&#305;&#287;&#305;
kan&#305;tlanm&#305;&#351;t&#305;r. Di&#287;er paraneoplastik
hastal&#305;klarda (�zellikle intrasel�ler antijenlere kar&#351;&#305;
antikorlarla ili&#351;kili hastal&#305;klarda) anti-n�ronal antikorlar&#305;n
pasif nakli veya antijenlerle yap&#305;lan aktif immunizasyonla bug�ne dek
hayvan modellerinde hastal&#305;k olu&#351;turulamam&#305;&#351;t&#305;r. H�cre
membran&#305; antijenlerine (�rne&#287;in voltaja duyarl&#305; potasyum
kanal&#305; ve N-metil D-aspartat tipi glutamat resept�r� ile ili&#351;kili
limbik ensefalit) kar&#351;&#305; antikorlarla ili&#351;kili paraneoplastik
sendromlarda serum ve BOS antikor titreleri ile klinik bulgular&#305;n
a&#287;&#305;rl&#305;&#287;&#305; aras&#305;nda ili&#351;ki bulunmaktad&#305;r.
Ancak h�cre i�i antijenlerle (�rne&#287;in Hu, Yo, Ma) ili&#351;kili
sendromlarda tedaviyle serum veya BOS�ta antikor titresi d�&#351;se de klinik
bulgularda d�zelme olmaz. Bug�n bu antikorlar daha �ok tan&#305;da yol
g�sterici olmaktad&#305;r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p style='margin:0cm;margin-bottom:.0001pt'><b><span lang=TR style='font-size:
13.5pt;font-family:Tahoma;color:black;mso-ansi-language:TR'>Tablo 7.
Paraneoplastik sendromlarda otoantikorlar</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> </span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p style='margin:0cm;margin-bottom:.0001pt'><span lang=TR style='mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span
style='mso-spacerun:yes'>�������������������������
</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:480;mso-padding-alt:0cm 5.4pt 0cm 5.4pt;mso-border-insideh:
 .5pt solid windowtext;mso-border-insidev:.5pt solid windowtext'>
 <tr style='mso-yfti-irow:0'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:
  TR'>Antikor&nbsp;&nbsp;</span></b><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kanser&nbsp;&nbsp;</span></b><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sendrom</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-Hu&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>KHAK&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>PEM / SSN<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-Yo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Meme,
  jinekolojik<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>SCD <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-Ri&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Meme,
  jinekolojik&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>POMA<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-amfifizin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Meme&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�Stiff-person�,
  limbik ensefalit<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-VGCC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>KHAK&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>LEMS, SCD<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-Ma&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�e&#351;itli<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Beyinsap&#305;
  ensefaliti, SCD<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-Ma2
  (Ta)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Testis&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Limbik
  ensefalit, beyinsap&#305; ensefaliti<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-Tr&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Hodgkin
  hastal&#305;&#287;&#305; &nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>SCD<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-CAR&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>KHAK<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Retinopati<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-CV2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>KHAK&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>PEM / SCD
  /SSN<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;mso-yfti-lastrow:yes'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-NMDAR&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Over
  teratomu&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Limbik
  ensefalit<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>K&#305;saltmalar i�in metne bak&#305;n&#305;z</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>Tablo 8. Paraneoplastik sendromlarda altta yatan t�m�re g�re otoantikorlar.</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p style='margin:0cm;margin-bottom:.0001pt'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sendrom&nbsp;&nbsp;&nbsp;&nbsp;<span
style='mso-spacerun:yes'>��������������������� </span>T�m�r</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:480;mso-padding-alt:0cm 5.4pt 0cm 5.4pt;mso-border-insideh:
 .5pt solid windowtext;mso-border-insidev:.5pt solid windowtext'>
 <tr style='mso-yfti-irow:0'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>KHAK<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>KHAK-d&#305;&#351;&#305;<b>&nbsp;&nbsp;&nbsp;&nbsp;</b><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Meme/Over&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Lenfoma<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>SCD<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>ANNA1&nbsp;<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(anti-Hu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>APCA<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(anti-Yo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>anti-Tr<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>SSN&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>ANNA1&nbsp;<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(anti-Hu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(�)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>PEM<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>ANNA1&nbsp;<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(anti-Hu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>APCA<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(anti-Yo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;POMA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>ANNA2&nbsp;<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(anti-Ri)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Stiff-person&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(�)<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Anti-amfifizin<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>K&#305;saltmalar i�in metne bak&#305;n&#305;z<o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedavi</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
sendromlar&#305;n tedavisinde en �nemli yakla&#351;&#305;m altta yatan kanserin
tan&#305;s&#305; ve tedavisidir. Bu durumda n�rolojik tablo tamamen d�zelmese
de en az&#305;ndan stabilize olabilir. Bunun d&#305;&#351;&#305;nda steroidler,
intraven�z immunglobulin (IVIg), plazmaferez gibi immunsupresif veya
immunmod�lat�r tedaviler kullan&#305;labilir. Ancak olduk�a pahal&#305; olan bu
tedavilerle de �o&#287;u zaman y�z g�ld�r�c� sonu�lar al&#305;nmamaktad&#305;r.
Bununla beraber son y&#305;llarda voltaja duyarl&#305; potasyum kanal&#305; ve
N-metil D-aspartat tipi glutamat resept�r� antikorlar&#305; ile ili&#351;kili
limbik ensefalit ve voltaja duyarl&#305; kalsiyum kanal&#305; antikoru ile
ili&#351;kili Lambert-Eaton miyastenik sendromu ve serebellar dejenerasyon
olgular&#305;nda steroid, IVIg ve plazmaferez gibi y�ntemlerle y�ksek tedavi
ba&#351;ar&#305;s&#305; elde edilebilece&#287;i g�sterilmi&#351;tir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;l&#305;ca
Paraneoplastik Sendromlar </span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Baz&#305;
n�rolojik tablolar vard&#305;r ki, bunlar g�r�ld�&#287;�nde mutlaka
paraneoplastik sendrom akla gelmeli ve altta yatan bir t�m�r
ara&#351;t&#305;r&#305;lmal&#305;d&#305;r. �Klasik� paraneoplastik sendromlar
olarak da adland&#305;r&#305;labilecek bu tablolar aras&#305;nda subakut
serebellar dejenerasyon, opsoklonus-miyoklonus-ataksi sendromu, subakut duysal
n�ropati, Lambert-Eaton miyastenik sendromu gibi tablolar yer al&#305;r. 2004
y&#305;l&#305;nda uluslar aras&#305; bir konsorsiyum taraf&#305;ndan belirlenen
kriterlere g�re kesin paraneoplastik sendrom ad&#305;n&#305; vermek i�in
n�rolojik sendromun, antin�ronal antikorla birlikte bulunmas&#305; ve altta
yatan kanserin mevcut olmas&#305;, n�rolojik tablo ve kanserin ortaya
�&#305;k&#305;&#351;&#305;n&#305;n ise en fazla 5 y&#305;l ara ile
ger�ekle&#351;mesi gereklidir. Bu ko&#351;ullar&#305;n d&#305;&#351;&#305;nda
kesin paraneoplastik sendrom olarak adland&#305;r&#305;labilmek i�in
a&#351;a&#287;&#305;daki 4 se�enekten birine uymas&#305; gereklidir: 1.
�Klasik� n�rolojik sendrom ve kanser (en fazla 5 y&#305;l ara ile); 2. Kansere
e&#351;lik eden ve t�m�r�n tedavisi ile iyile&#351;en klasik olmayan sendrom
(spontan iyile&#351;ebilen bir hastal&#305;k olmamal&#305;); 3. Klasik olmayan
sendromla birlikte kanserin (en fazla 5 y&#305;l ara ile) ve antin�ronal
antikorlar&#305;n saptanmas&#305;; 4. N�rolojik sendrom klasik olsun veya olmas&#305;n,
kanser saptanamasa bile iyi karakterize edilmi&#351; (klasik)
otoantikorlar&#305;n saptanmas&#305; (Hu, Yo, Ri, vs). Bu kriterleri tam olarak
kar&#351;&#305;lamayan geri kalan b�t�n durumlar&#305;n da olas&#305;
paraneoplastik sendrom olarak adland&#305;r&#305;lmas&#305; �nerilmi&#351;tir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Subakut
serebellar dejenerasyon (SCD)</span></i></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>: �Klasik� paraneoplastik sendromlar&#305;n en
s&#305;k g�r�lenidir. Haftalar-aylar i�inde ilerleyen bu serebellar sendromda;
g�vde ve taraf ataksisi, dizartri, horizontal ve vertikal nistagmus ortaya
�&#305;kar, bir s�re sonra a&#287;&#305;r sekelle tablo sabitle&#351;ir. Ender
olarak diplopi, i&#351;itme kayb&#305;, yutma zorlu&#287;u, piramidal bulgular
ve polin�ropati e&#351;lik edebilir. Erken BT/MR normaldir; ge� d�nemde
serebellar atrofi, bazen serebellum ak maddesinde hiperintensite g�r�lebilir.
Histopatolojide yo&#287;un ve selektif Purkinje h�cre kayb&#305; s�z konusudur.
Serebellumda erken evrelerde yo&#287;un inflamasyon bulgular&#305; g�r�l�rken,
hastal&#305;&#287;&#305;n ileri evrelerinde inflamatuvar h�creler kaybolur.
SCD�de en s&#305;k anti-Yo antikorlar&#305; (= �anti-purkinje cell�
antikor�APCA) saptan&#305;r. Hemen daima meme, over veya di&#287;er jinekolojik
kanserlerle ili&#351;kilidir; ancak lenfoma veya akci&#287;er kanserinde de
g�r�lebilir. Anti-Yo antikorlar&#305; immunhistokimyasal olarak sadece Purkinje
h�crelerinin sitoplazmas&#305; ile ve sadece SCD�linin t�m�r� ile reaksiyon
verir. Bu antikor 34 kD ve 62 kD proteinleri tan&#305;r. Daha seyrek orarak
anti-Hu (k���k h�creli akci&#287;er kanseri), anti-Zic4 (k���k h�creli
akci&#287;er kanseri) ve anti-Tr (lenfoma) ile ili&#351;kili SCD g�r�lebilir.
Bu sonuncusu, di&#287;er paraneoplastik sendromlar&#305;n aksine 20-40 ya&#351;
aras&#305; erkeklerde daha s&#305;kt&#305;r ve genellikle SCD lenfoma
tan&#305;s&#305;ndan sonra ortaya �&#305;kar; remisyon da s&#305;kt&#305;r.
Oysa di&#287;er SCD�ler tedaviye pek cevap vermezler. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
ensefalomiyelit/ subakut duysal n�ropati (PEM/SSN): M</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>SS�nin farkl&#305;
b�lgelerinin, arka k�k, gangliyon ve otonomik liflerin etkilenebildi&#287;i
immunolojik mekanizmalarla olu&#351;an inflamatuvar bir hastal&#305;kt&#305;r.
�n planda hipokampus (limbik ensefalit), beyin sap&#305; (beyinsap&#305;
ensefaliti), diensefalon, serebellumun Purkinje h�creleri (serebellar
dejenerasyon), dorsal k�k-gangli<span style='color:white'>y</span>onu (duysal
n�ronopati), medulla spinalis (miyelit) ve sempatik ve parasempatik sinir ve
gangliyonlar (otonomik bulgular) tutulur. Hemen daima anti-Hu antikorlar&#305;
(= anti-n�ronal n�kleer antikor tip I�ANNA1) ile ili&#351;kilidir.
Olgular&#305;n %70�inden fazlas&#305;nda k���k h�creli akci&#287;er kanseri
(KHAK) ile birlikte g�r�l�r. Bunun d&#305;&#351;&#305;nda adrenal, prostat,
n�roblastom ve farkl&#305; t�r akci&#287;er kanserleri gibi di&#287;er
kanserlerle de g�r�lebilir. Patolojide klinik olarak tutulan b�lgeye bakmaks&#305;z&#305;n
yayg&#305;n lenfositik infiltrasyon ile birlikte n�ron kayb&#305;; t�m�rde de
benzer infiltrasyon g�r�l�r. Anti-Hu antikorlar&#305; immunhistokimyasal olarak
periferik ve santral b�t�n n�ronlar&#305;n nukleusu ile ve b�t�n KHAK�lerle
reaksiyon verir. Paraneoplastik sendromsuz KHAK�de de �ok d�&#351;�k titrede
bulunabilir (%15). Bu antikorlar 35-40 kD proteinleri tan&#305;r. Klinik
olgular&#305;n % 25�inde unifokal iken (SSN, limbik ensefalopati veya
beyinsap&#305; ensefaliti), %75 olguda multifokaldir (SSN, limbik ensefalopati,
beyinsap&#305; ensefaliti, SCD, motor n�ron-benzeri, otonom n�ropati, g�rme
azalmas&#305;; %3 diff�z PEM gibi ). Anti-Hu d&#305;&#351;&#305;nda anti-CV2
(KHAK, timoma), anti-Ma (testis kanseri), anti-amfifizin (meme, KHAK), voltaja
duyarl&#305; potasyum kanal&#305; (KHAK, timoma) ve N-metil D-aspartat
resept�r� (over teratomu) antikorlar&#305; ile ili&#351;kili PEM olgular&#305;
da bildirilmi&#351;tir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
SSN alttan ba&#351;layan parestezi-dizestezi ile ortaya �&#305;kar,
g�nler/haftalar i�inde ilerler. Semptomlar genellikle asimetriktir, derin
tendon refleksleri s&#305;kl&#305;kla kay&#305;pt&#305;r, derin duyu belirgin
derecede bozulur ve kas g�c� normaldir. Baz&#305; olgularda derin duyu
kayb&#305; bask&#305;n bulgudur. Bu y�zden duysal ataksi ve ellerde
ps�doatetoid hareketler s&#305;kl&#305;kla g�zlenir. Tutulan b�lgeler arka k�k
ve gangliyon oldu&#287;undan BOS incelemesi s&#305;kl&#305;kla patolojik sonu�lar
verir. S&#305;kl&#305;kla anti-Hu ve anti-CV2 antikorlar&#305; ile
ili&#351;kilidir. EMG�de duysal aksonal polin�ropatiyle uyumlu olarak duysal
aksiyon potansiyelleri kaydedilemez, buna kar&#351;&#305;n motor iletiler
normal s&#305;n&#305;rlardad&#305;r. Limbik ensefalopati ise g�nler/haftalar i�inde
ilerleyen davran&#305;&#351;-duygudurum de&#287;i&#351;iklikleri, konf�zyon,
n�betler, halusinasyonlarla ortaya �&#305;kar. BT/MR normal olabilirse de bazen
meziyal temporal lezyon/kontrast tutulumu g�r�lebilir. Anti-Hu sendromunda
otonom n�ropati �nemli bir morbidite ve mortalite nedenidir. Tek
ba&#351;&#305;na veya SSN ile birlikte g�r�l�r. Progresif otonom bozukluklarla
karakterizedir. Bazen t�m�r �&#305;kar&#305;l&#305;nca stabilize olabilirse de
s&#305;kl&#305;kla �l�m nedeni otonom n�ropati olur. Anti-Hu sendromunda klinik
bulgular genellikle tedaviden yararlanmaz. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
opsoklonus-myoklonus-ataksi (POMA): </span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Opsoklonus sakkadik
stabilitenin bozulmas&#305; sonucu ortaya �&#305;kan istemsiz, aritmik, �ok
y�nl�, y�ksek amplit�dl� konjuge sakkadik g�z hareketleri olarak tan&#305;mlanabilir.
POMA sendromunda opsoklonusa s&#305;kl&#305;kla miyokloni, titubasyon ve g�vde
ataksisinin bask&#305;n; taraf ataksisinin geri planda oldu&#287;u serebellar
sendrom e&#351;lik eder. �ocuklarda olgular&#305;n % 50�sinde altta yatan
n�roblastoma s�z konusudur ve di&#287;er yandan n�roblastomal&#305;
�ocuklar&#305;n % 2�sinde POMA saptan&#305;r. Eri&#351;kinde ise genellikle
non-paraneoplastiktir. T�m�rle birliktelik % 20-25 olguda s�z konusudur. MR ve
BOS incelemeleri genellikle normaldir. Son y&#305;llarda yap&#305;lan �al&#305;&#351;malar
tutulan hedef MSS b�lgesinin serebellumun fastigial nukleusu oldu&#287;unu
g�stermi&#351;tir. Bu gruptaki olgular&#305;n �nemli bir k&#305;sm&#305;nda
antikor g�sterilememektedir. Eri&#351;kinlerde POMA olgular&#305;n&#305;n k���k
bir k&#305;sm&#305; anti-Ri antikorlar&#305; (= anti-n�ronal n�kleer antikor
tip II�ANNA2) ile ili&#351;kilidir. Altta yatan kanserler s&#305;kl&#305;kla
meme ve di&#287;er jinekolojik t�m�rlerdir. Daha seyrek olarak k���k h�creli
akciger kanseri (KHAK), mesane kanseri vs. ile ili&#351;kili olabilir. Anti-Ri
antikorlar&#305; immunhistokimyasal olarak b�t�n santral n�ronlar&#305;n
nukleuslar&#305; ile reaksiyon verir; ANNA1�in aksine periferik n�ronlarla
reaksiyon vermez. Bu antikor 55 kD ve 80 kD proteinleri tan&#305;r. Bu
sendromla ili&#351;kili antikorlar&#305;n g�n�m�zdeki y�ntemlerle kolayca
g�sterilemeyen, muhtemelen h�cre membran&#305; ve aksonuna ba&#287;lanan
antikorlar oldu&#287;unu destekleyen �al&#305;&#351;malar vard&#305;r.
POMA�l&#305; hastalarda t�m�r rezeksiyonunun ard&#305;ndan yap&#305;lacak
kortikosteroid, IVIg, plazmaferez gibi tedavi y�ntemleri ile remisyon
g�r�lebilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kanserle
ili&#351;kili retinopati </span></i></b><b><i><span lang=TR style='font-family:
Symbol;mso-ansi-language:TR'>[</span></i></b><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>�Cancer associated retinopathy�
(CAR)</span></i></b><b><i><span lang=TR style='font-family:Symbol;mso-ansi-language:
TR'>]</span></i></b><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Epizodik g�rme azalmalar&#305;, gece k�rl�&#287;�, &#305;&#351;&#305;k
parlamalar&#305;, fotosensitivite, renkli g�rme azalmas&#305; ile ba&#351;lar,
progresif a&#287;r&#305;s&#305;z g�rme kayb&#305; geli&#351;ir (�nce tek
yanl&#305;, daha sonra iki yanl&#305; olabilir). G�z muayenesinde skotomlar,
g�rme keskinli&#287;inde azalma, retinada arterioler daralma, pigment epiteli
birikimi, bazen vitrede h�cre g�r�lebilir. Patolojide fotoresept�r / gangliyon
h�crelerinin selektif kayb&#305; s�z konusudur. Genellikle KHAK (%60) ve
jinekolojik t�m�rler gibi di&#287;er baz&#305; kanserlerle ili&#351;kili
olabilir. Anti-CAR antikorlar&#305; saptanabilir. Bu antijenler retinal
fotoresept�r h�crelerde rekoverin (23-48 kD) veya di&#287;er retinal
proteinleri tan&#305;yabilir. Melanoma ile ili&#351;kili retinopatide ise
antikorlar&#305;n hedefi fotoresept�rler de&#287;il retinan&#305;n bipolar
h�creleridir. &nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�Stiff-person�
sendromu:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> S&#305;kl&#305;kla (%80) non-paraneoplastiktir. Paraneoplastik formu
anti-amfifizin antikorlar&#305; ile birlikte g�r�l�r ve s&#305;kl&#305;kla meme
kanseri veya KHAK ile ili&#351;kilidir. Progresif rijidite, refleks-spazmlar,
lomber lordoz art&#305;&#351;&#305; ile gider; ba&#351;ka n�rolojik bulgu
olmaz. Bazen aksiyal kaslar yerine taraflarda bask&#305;n olabilir. Patolojik
olarak �kronik spinal intern�ronitis� s�z konusudur. BOS inflamatuvar
�zellikler g�sterir. EMG�de s�rekli motor �nit aktivitesi izlenir. Anti-amfifizin
antikorlar&#305; immunhistokimyasal olarak n�ronlar&#305;n presinaptik
u�lar&#305;yla ve dendritlerle reaksiyon verir ve 128 kD proteini tan&#305;r.
Semptomatik tedavi olarak benzodiazepinler, baklofen yararl&#305; olabilir.
Di&#287;er paraneoplastik sendromlardan farkl&#305; olarak t�m�r rezeksiyonu,
kortikosteroid ve IVIg ile tedavi genellikle m�mk�nd�r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Lambert
Eaton Miyastenik Sendromu (LEMS):</span></i></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> LEMS hastalar&#305;n&#305;n % 60�&#305; KHAK
(veya di&#287;er k���k h�creli kanserlerle) ili&#351;kilidir; % 40�&#305;nda
ise non-paraneoplastiktir. KHAK�li hastalar&#305;n&#305;n %3��nde LEMS saptanm&#305;&#351;t&#305;r.
Paraneoplastik LEMS erkeklerde daha s&#305;kt&#305;r. Presinaptik b�lgede,
voltaj kap&#305;l&#305; kalsiyum kanallar&#305;na kar&#351;&#305;
antikorlar&#305;n (anti-VGCC) Asetilkolin (Ach) sal&#305;n&#305;m&#305;n&#305;
azaltmas&#305; sonucu hastal&#305;k meydana gelir. Deney hayvanlar&#305;nda
anti-VGCC injeksiyonunun hastal&#305;&#287;&#305; olu&#351;turdu&#287;u
g�sterilmi&#351;tir. Klinik olarak �abuk yorulma, g��s�zl�k ve �ift g�rme
yak&#305;nmalar&#305; vard&#305;r. S&#305;kl&#305;kla a&#287;&#305;z
kurulu&#287;u, erkeklerde impotans gibi kolinerjik otonom bulgular e&#351;lik
edebilir. Muayenede zay&#305;f bulunan kas g�c�, hastan&#305;n o kas&#305; �al&#305;&#351;t&#305;rmas&#305;
sonucu fasilite olur ve normale d�ner. Bulber tutulum g�r�lmez; solunum
g��l�&#287;� olabilir. Refleks kayb&#305; vard&#305;r, ama eforla
pozitifle&#351;ebilir. EMG�de 10-20 Hz�lik repetetif stim�lasyonda �increment�
g�r�lmesi veya motor yan&#305;tlar&#305;n kuvvetli ve k&#305;sa s�reli istemli
kas&#305; ile belirgin amplit�d art&#305;&#351;&#305; g�stermesi tan&#305;
koydurucudur. Plazmaferez ve immunsupresyona cevapl&#305; olabilir. Semptomatik
tedavide guanidin, 3-4 DAP (diaminopiridin), antikolinesteraz yararl&#305;
olabilir. Anti-VGCC antikorlar&#305; olan olgularda LEMS tablosuna SCD de
e&#351;lik edebilir ve bu olgularda k���k h�creli akci&#287;er kanseri ve
anti-Hu bulunma olas&#305;l&#305;&#287;&#305; y�ksektir. Son zamanlarda, SOX
isimli bir n�ronal antijeni tan&#305;yan ve serebellumun Bergman glia h�crelerinin
nukleuslar&#305;na ba&#287;land&#305;&#287;&#305; i�in anti-glial n�kleer
antikor (AGNA) ad&#305; verilen antikorlar&#305;n paraneoplastik LEMS
olgular&#305;n&#305;n yar&#305;s&#305;nda saptand&#305;&#287;&#305; ve bu
y�zden bu antikorlar&#305;n potansiyel bir tan&#305; y�ntemi olarak
kullan&#305;labilece&#287;i bildirilmektedir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Polimiyozit
/ Dermatomiyozit (PM/DM):</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> K���k bir grup olguda paraneoplastiktir.
Ya&#351;l&#305;larda ve dermatomiyozitte kanserle ili&#351;ki �ok daha
s&#305;kt&#305;r. Meme, akci&#287;er, over, mide, prostat, kolon kanserleri ve
Hodgkin hastal&#305;&#287;&#305; ile ili&#351;kili olabilir. Bilinen bir
otoantikor yoktur. Immun arac&#305;l&#305; bir vask�lopatidir. T�m�r tedavisi,
immunsupresif tedavi ve IVIg yararl&#305; olabilir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Subakut
duysal-motor n�ropati:</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Seyrek olarak paraneoplastik nedenlidir. Genellikle
akci&#287;er kanseri ile ili&#351;kilidir. H&#305;zl&#305; ilerleyen distal
simetrik polin�ropati, nadiren kronik inflamatuvar demiyelinizan polin�ropati
benzeri seyir g�r�lebilir. EMG�de genellikle aksonal polin�ropati g�r�l�r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Di&#287;er Paraneoplastik Sendromlar</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Anti-Ma ili&#351;kili sendromlar</span></i></b><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>:</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Anti-Ma1 ve Ma2 (Ta) antikorlar&#305; paraneoplastik beyinsap&#305;, limbik sistem
ve diensefalon bulgular&#305; olan olgularda saptanabilirler. Anti-Ma
sendromunda mezensefalon ve diensefalonun �n planda tutulmas&#305;na
ba&#287;l&#305; olarak zengin ok�lomotor bulgular, parkinsonizm, uyku
bozuklu&#287;u ve hiponatremi s&#305;kl&#305;kla g�zlenir. Anti-Ma2 antikoru
daha s&#305;k olarak saptan&#305;r ve olgular&#305;n �o&#287;u testis kanseri
olan gen� erkeklerdir. Daha nadiren �zellikle ya&#351;l&#305; erkeklerde ve
kad&#305;nlarda anti-Ma1 ve daha az olarak anti-Ma2 antikoru ile akci&#287;er,
meme, parotis, kolon kanserleri aras&#305;nda ili&#351;ki bildirilmi&#351;tir.
Anti-Ma antikorlar&#305; immunhistokimyasal olarak santral n�ronlar&#305;n ve
testis germ h�crelerinin nukleolusu ile ve sorumlu kanserle reaksiyon verir ve
37-40 kD proteinleri tan&#305;r. Anti-Ma2 (Ta) ile ili&#351;kili testis t�m�rl�
olgularda prognoz di&#287;er paraneoplastik sendromlara g�re daha iyidir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Nekrotizan miyelopati</span></i></b><i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>:</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> l�semi,
lenfoma, akci&#287;er kanseri ile ili&#351;kili olabilir. Asandan parapleji ve
radik�ler a&#287;r&#305; g�r�l�r. MR�da omurilik normal veya &#351;i&#351;
g�r�nebilir, da&#287;&#305;n&#305;k kontrast tutulumu g�sterebilir. Patolojide
omurilikte b�t�n tabakalarda inflamasyonsuz nekroz g�r�l�r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Miyelit</span></i></b><i><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>:</span></i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Genellikle anti-Hu sendromunun
par�as&#305; olarak kar&#351;&#305;m&#305;za �&#305;kar. MR normaldir veya
kontrast tutulumu g�steren lezyon g�r�lebilir. Patolojide �n ve arka boynuzda
bask&#305;n inflamasyon vard&#305;r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Paraneoplastik motor n�ron sendromlar&#305;</span></i></b><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>: </span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lenfoma
ve di&#287;er baz&#305; kanserlerde g�r�l�r; �� grupta incelenebilir:
1.h&#305;zl&#305; ilerleyici motor n�ron hastal&#305;&#287;&#305; + anti-Hu
(KHAK, prostat) ; 2.primer lateral skleroz + antikorsuz (meme); 3.ALS-benzeri +
antikorsuz (meme, jinekolojik, Hodgkin,(KHAK-d&#305;&#351;&#305;). Bu ���nc�
grupta rastlant&#305;sal olma ihtimali y�ksektir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Kaynaklar</span></i></b><b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>:</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>1.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Abrey L, Batchelor T, Fereri A, ve ark. Report of an
international workshop to standardize baseline evaluation and response criteria
for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034-5043.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>2.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Adams RD, Victor M, Ropper AH (edit�rler). Principles of
Neurology, 6<sup>th</sup> edition. Mc Graw Hill, New York, 1997. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>3.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Aminoff MJ (editor). Neurology and general medicine (4.
bask&#305;). Churchill Livingstone Elsevier, Philadelphia, 2008.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>4.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Balm M, Hammack J. Leptomeningeal carcinomatosis.
Presenting features and prognostic factors. <i>Arch Neurol</i> 1996; 53: 626. </span><span
lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>5.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Bataller L, Kleopa KA, Wu GF, ve ark. Autoimmune limbic encephalitis
in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry.
2007;78:381.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>6.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Boyaciyan A, Oge AE, Yazici J, Aslay I, Baslo A.
Electrophysiological findings in patients who received radiation therapy over
the brachial plexus: a magnetic stimulation study. Electroencephalogr Clin
Neurophysiol 1996; 101: 483. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:115%'><span
lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:
TR'>7.</span><span lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>Bradley WG,
Daroff RB, Fenichel GM, Jankovic J (editor). Neurology in Clinical Practice
(5th Edition). Butterworth-Heinemann-Elsevier, Philadelphia 2008.</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:115%'><span
lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:
TR'>8.</span><span lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>Brandsma D,
van den Bent MJ. Molecular targeted therapies and chemotherapy in malignant
gliomas. Current Opinion in Oncology 2007; 19: 598-605.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>9.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Dalmau J, Tuzun E, Wu HY, ve ark.. Paraneoplastic
anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian
teratoma. Ann Neurol. 2007;61:25.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>10.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Dalmau JO, Posner JB. Paraneoplastic syndromes. Arch
Neurol 1999; 56: 405. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>11.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Daumas-Duport C, Scheithauer B, O�Fallon J, Kelly P.
Grading of astrocytomas: a simple and reproducible method. Cancer 1988; 62:
2152. </span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:115%'><span
lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:
TR'>12.</span><span lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:
TR'>&nbsp;&nbsp; </span><span lang=TR style='font-size:10.0pt;line-height:115%;
font-family:Tahoma;mso-ansi-language:TR'>DeVito VT, Hellman S, Rosenberg SA.
Cancer: Principles and Practice of Oncology 7th Edition. Lippincot Williams and
Willkins, Philadelphia 2005.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>13.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Dropcho EJ. Autoimmune central nervous system
paraneoplastic disorders: mechanisms, diagnosis, and therapeutic options. Ann
Neurol 1995; 37 (S1): S102.</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:115%'><span
lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:
TR'>14.</span><span lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:
TR'>&nbsp;&nbsp; </span><span lang=TR style='font-size:10.0pt;line-height:115%;
font-family:Tahoma;mso-ansi-language:TR'>Graus F, Delaterre JY, Antoine JC,
Dalmau J, Giometto B, Grisold W, ve ark. Recommended diagnostic criteria for paraneoplastic
neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>15.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Gultekin SH, Rosenfeld MR, Voltz R, ve ark.
Paraneoplastic limbic encephalitis: neurological symptoms, immunological
findings and tumour association in 50 patients. Brain. 2000;123:1481. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>16.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Hardell L, Nasman A, Pahlson A, Hallquist A, Hansson Mild
K. Use of cellular telephones and the risk for brain tumours: A case-control
study. <i>Int J Oncol</i> 1999; 15: 113. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>17.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Hildebrand JG. Prospects in glioma therapy. J Neurol
1999; 246: 3. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>18.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Hoang-Xuan K. Primary central nervous system lymphoma in
immunocompetent patients. J Neurol 1999; 246: 3. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>19.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Jaeckle KA. Autoimmunity in paraneoplastic neurological
syndromes: closer to the truth? Ann Neurol 1999; 45: 143. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>20.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Kadan-Lottick N, Sklusarek M, Gurney J. Decreasing
incidence rates of primary central nervous system lymphoma. Cancer 2002; 95:
193.</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:115%'><span
lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:
TR'>21.</span><span lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:
TR'>&nbsp;&nbsp; </span><span lang=TR style='font-size:10.0pt;line-height:115%;
font-family:Tahoma;mso-ansi-language:TR'>Kan P, Simonsen SE, Lyon JL, Kestle
JR. Cellular phone use and brain tumor: a meta-analysis. J Neurooncol 2008; 86:
71-78.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>22.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Kleihues P, Cavenee W (edit�rler). Pathology and
Genetics- Tumours of the Central Nervous System. International Agency for
Research on Cancer, Lyon, 1997. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>23.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Kun LE, Gajjar A, Pollack IF. Pediatric brain tumors.
&#304;�inde: Perry MC (edit�r), American Society of Clinical Oncology 1999
Educational Book. American Society of Clinical Oncology, Alexandria, 1999. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>24.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Mittl RL, Yousem DM. Frequency of unexplained meningeal enhancement
in the brain after lumbar puncture. AJNR Am J Neuroradiol 1994; 15: 633-638.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>25.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Patchell RA (edit�r). Neurologic Complications of
Systemic Cancer. Neurologic Clinics, Volume 9/4. WB Saunders Company,
Philadelphia, 1991. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>26.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Posner J. Neurologic complications of cancer. FA Davis
Company, Philadelphia, 1995. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>27.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Rosenblum ML (edit�r). The Role of Surgery in Brain Tumor
Management. Neurosurgery Clinics of North America. WB Saunders Company,
Philadelphia, 1990. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>28.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Rowland LP. Merritt�s Textbook of Neurology, 9<sup>th</sup>
edition. Williams and Wilkins, Philadelphia, 1995. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>29.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>WasserstromWR, Glass JP, Posner JB. Diagnosis and
treatment of leptomeningial metastases from solid tumors: experience with 90
patients. Cancer 1982; 49 (4): 759-772.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

</div>

</body>

</html>
